
Cumulative Index

Volume 44, Numbers 1-4, 2001

- A**
Abacavir
hypersensitivity reaction to, 182
for pediatric AIDS, 243
use in pregnancy, preclinical and clinical data relevant to, 182
ABC. *See* Abacavir
Abdominal pain, leiomyoma-related, 364, 385
Abortion
elective, among HIV-infected (AIDS) patients, 289
spontaneous. *See also* Pregnancy loss
in HIV-infected (AIDS) patients, 154, 198
with uterine leiomyomas, 385
Abruptio placentae, uterine leiomyomas and, 364
Abstinence, for adolescents, 114
Acne, reduction of, oral contraceptives and, 62
Aconite, Association of Official Agricultural Chemists' task force on dietary supplements and, 789
Acquired immunodeficiency syndrome (AIDS). *See also* Human immunodeficiency virus 1 (HIV-1) infection
antiphospholipid antibodies in, 48
in children. *See* Pediatric AIDS
end-of-life issues in, 300
ethical issues related to, 300
legal issues related to, 300
opportunistic processes in, 167
prevention of, in pregnancy, 182
pediatric. *See* Pediatric AIDS
risk factors for, 154
in women
age distribution of, 154
epidemiology of, 154
mortality rate for, 154
racial distribution of, 154
risk factors for, 154
Actaea racemosa. *See* Black cohosh
ACTG 076. *See* AIDS Clinical Trials Group protocol 076
Activated partial thromboplastin time, in antiphospholipid syndrome, 36
Acupressure
definition of, 704
for labor analgesia, 704
for morning sickness, 653
in pregnancy, 681
Acupuncture
clinical studies of, 801
complications of, 704
definition of, 681
efficacy of, clinical trial evidence of, 902
FDA and, 801
in labor, 681
for labor analgesia, 681, 704
for labor induction, 681
mechanisms of action of, 704
and neonatal healing, 750
preclinical studies of, 801
in pregnancy, 681
principles of, 681, 704
providers of, 704
research on, 704
theory of, 801
therapeutic goal of, 681
Adaptogen, ginseng as, 853
Adeno-associated virus, as vector for gene therapy, 425
Adenomatoid tumor(s), uterine, 350
Adenomyoma, 350
atypical polypoid, 350
Adenomyosis
after laparoscopic myomectomy, 401
diagnosis of, 412
and outcome of uterine artery embolization for myomas, 412
and uterine leiomyomas, differentiation of, 385
Adenovirus, as vector for gene therapy, 425
Adhesion barriers, 401
Adhesion molecules, endothelial cell production of, anti-phospholipid antibody-induced, 11, 20
Adhesions, formation of, postmyomectomy, 401
Adnexal mass. *See also* Ovarian cancer; Tubal cancer
benign and malignant
architectural features of, 485
differentiation of, 485, 495
laparoscopic removal of, technical feasibility of, 495
at low risk for malignancy, laparoscopic management of, 495
management of, laparoscopy in, 495
at moderate risk for malignancy, laparoscopic management of, 495
guidelines for, 495
Adolescents
abstinence among, 114
cognitive skills of, health-care implications of, 114
contraception for, 114
counseling about, general principles for, 114
methods of, 114
health care for

Page numbers indicate first page of relevant article.

- age-appropriate approach for, 114
- cognitive considerations in, 114
- consistency in messages and, 114
- HIV infection in. *See* Pediatric AIDS
- pregnancy rate among
 - trend in, 114
 - in U.S. *versus* other developed nations, 114
- serial monogamy among, 114
- sexuality
 - parents and, 114
 - and pregnancy rate, 114
 - and sexually transmitted disease, 114
- Advance directive(s), for HIV-infected (AIDS) patients, 300
- Age
 - and hemorrhagic stroke risk, 62
 - and ischemic stroke risk, 62
 - and myocardial infarction risk, 62
- Agenerase. *See* Amprenavir
- Aging, growth hormone use in, 893
- Agnus castus*. *See* Chasteberry
- AIDS. *See* Acquired immunodeficiency syndrome (AIDS)
- AIDS Clinical Trials Group protocol 076, 182, 198, 210, 289
- Alaskan Natives. *See* Native Americans
- Alcohol, and breast cancer risk, 478
- Allicin, 814
- Alternative medicine. *See* Complementary and alternative medicine
- Alzheimer disease
 - ginkgo for, 824
 - prevention, hormone replacement therapy and, 464
- Amenorrhea
 - in HIV-infected (AIDS) patients, 226
 - with injectable long-acting contraceptives, 73
- American College of Obstetricians and Gynecologists
 - guidelines for vaginal birth after cesarean delivery, 561, 622
 - policy statement on home birth, 671
- American ginseng. *See* Ginseng
- American Indians. *See* Native Americans
- American Spiritual History, 661
- Amniocentesis, Native Americans and, 661
- Amprenavir
 - contraindications to, 182
 - for pediatric AIDS, 243
 - use in pregnancy, preclinical and clinical data relevant to, 182
- Amsterdam criteria, for diagnosis of hereditary nonpolyposis colorectal cancer, 450
- Anabolic steroids
 - adverse effects and side effects of, 880
 - for menopausal symptoms, 880
 - over-the-counter, 880
- Anal intraepithelial neoplasia, in HIV-infected (AIDS) patients, 226
- Ancient change, in soft tissue tumors, 350
- Andractim, 880
- Androgens
 - adverse effects and side effects of, 880
 - and breast cancer, 880
 - endometrial effects of, 880
 - and growth of uterine leiomyomas, 372
 - levels of, in women, 880
 - for menopausal symptoms, 880
 - metabolism of, 880
 - over-the-counter, 880
 - potential therapeutic effects in women, 880
 - preparations of, 880
 - therapy with, for uterine leiomyomas, 372
- Androstenedione, over-the-counter, 880
- Anemia
 - in pediatric AIDS, 243
 - as presenting HIV-related condition, 167
 - and vertical transmission of HIV, 198
- Angelica polymorpha*. *See* Dong quai
- Angiogenesis, inhibitors of, therapeutic potential of, for uterine leiomyomas, 327
- Angiogenic growth factors, in uterine leiomyomas, 327, 372
- Annexins, antiphospholipid antibodies and, 11, 20
- Anticardiolipin antibodies
 - antiphospholipid syndrome caused by, 36
 - in diagnosis of antiphospholipid syndrome, 48
 - laboratory assessment for, 36, 48
 - historical perspective on, 48
 - positive results on, disorders causing, 48
 - standardization of, 48
 - management of, during pregnancy, 20
 - and risk of pregnancy loss, 2
- Anticoagulation
 - acute, in antiphospholipid syndrome, 36
 - chronic, in antiphospholipid syndrome, 36
 - complications of, 36
- Antidepressant(s)
 - St. John's wort as, 824
 - and St. John's wort, interactions of, 824
- Antifactor Xa, monitoring, in antiphospholipid syndrome, 36
- Antifibrotic drugs, therapeutic potential of, for uterine leiomyomas, 327
- Antiphospholipid antibodies. *See also* Antiphospholipid syndrome
 - and annexins, 11, 20
 - and antithrombin 733, 11
 - and eicosanoid balance, 11, 20
 - and endothelial cells, 11, 20
 - and glycosaminoglycans, 11
 - and infertility, 29
 - laboratory assessment for
 - sensitivity of, 48
 - specificity of, 48
 - tests used for, 48
 - other than lupus anticoagulant and anticardiolipin antibodies, and risk of pregnancy loss, 2
 - and platelets, 11
 - and protein C-protein S pathway, 11, 20
 - testing for, 1, 48
 - and in vitro fertilization-embryo transfer, 29
- Antiphospholipid syndrome. *See also* Antiphospholipid antibodies
 - with antibodies other than lupus anticoagulant or anticardiolipin
 - definition of, 2, 20
 - and pregnancy, 20
 - classification system for, 2, 20
 - clinical manifestations of, 36
 - clinical spectrum of, 20
 - definite (classic)

- definition of, 2, 20
- management during pregnancy, 20
- postpartum treatment of, 20
- preconception counseling in, 20
- prevention of pregnancy loss in, 20
- thromboprophylaxis in, 20
- diagnosis of
 - clinical criteria for, 2
 - laboratory criteria for, 36
 - tests used in, 48
- fetal distress in, 2
- fetal growth restriction in, 2
- fetal loss in, 11
 - placental histopathology with, 11
- hypercoagulable state in, generation of, 11
- laboratory assessment for, 1, 36, 48
- with low levels of antibodies
 - definition of, 2, 20
 - treatment of, in pregnancy, 20
- management of
 - in pregnancy, 20
 - state of the art, 1
- neonatal outcomes in, 20
- obstetric complications of, 2, 20. *See also* Pregnancy loss
 - other than pregnancy loss, 2
- pathogenesis of, 1, 20, 36
- placental histopathology in, mechanisms of, 11
- preeclampsia in, 2
- pregnancy loss in, 11, 20
- preterm delivery in, 2
- thrombosis in, 36
 - acute treatment of, 36
 - chronic treatment of, 36
 - platelet activation and, 11
 - in pregnancy, 2
 - recurrence rates for, 36
 - risk factors for, 36
- uteroplacental insufficiency in, 2
- Antiprogestins, for uterine leiomyomas, 372
- Antiretrovirals in Pregnancy Registry, 182, 243
- Antiretroviral therapy. *See also* Highly active antiretroviral therapy (HAART)
 - adherence to, 182, 243
 - agents for, 167
- carcinogenicity of, 182, 210, 243
- combination
 - for pediatric AIDS, 243
 - in pregnancy, 182, 243
 - agents for, 182
 - monitoring of, 182
 - regimens for, 182
 - toxicity of, 182, 243
- discontinuation of, in first trimester, 154, 182
- drug interactions with, 182
- effect on perinatal transmission of HIV, 154, 243
- guidelines for, 167, 243
- initiation of, indications for, 167, 182, 243
- mitochondrial toxicity of, 182, 210, 243
- neonatal, 210, 243
- for pediatric AIDS, 243
 - adverse effects and side effects of, 243
 - switching drugs in, 243
- pharmacokinetics of, in pregnancy, 182
- postexposure prophylaxis, with occupational HIV exposure, 276
 - adverse effects and side effects of, 276
 - drug interactions with, 276
 - regimens for, 276
- postnatal, 210, 243
- in pregnancy, 182
 - benefits of, 182, 243
 - failure of, 182
 - long-term effects of, 182
 - and pregnancy outcome, 182
 - and prevention of vertical transmission of HIV, 210, 243
 - regimens for, 182, 243
 - risks of, 182, 243
 - standards of care for, 210
 - studies of, advances in (future directions for), 154
 - therapeutic efficacy of, 182
- principles of, 182
- regimens for, 167, 243
- resistance to, 276
 - causes of, 182
 - and prevention of vertical transmission of HIV, 210
- testing for, in pregnancy, 182
- and sexual risk behavior by HIV-infected women, 289
- teratogenicity of, 154, 182
- toxicity of, 182, 243
- Antithrombin 733, and pregnancy loss in antiphospholipid syndrome, 11
- Anxiety, kava kava and, 824
- APC gene, mutations, and colon cancer risk, 450
- Apoptosis, fibrotic disease and, 327
- Aristocholic acid, Association of Official Agricultural Chemists' task force on dietary supplements and, 789
- Arnica montana*, 704
- Aromatherapy
 - definition of, 704
 - for labor analgesia, 704
 - in neonatal intensive care unit, 750
 - for perineal discomfort, 704
- Artemisia vulgaris*. *See* Moxibustion
- Arterial occlusive disease, peripheral, ginkgo biloba for, 814
- Arterial thrombosis, in antiphospholipid syndrome, 36
 - acute treatment of, 36
- Artificial insemination, semen for, donor screening for HIV and, 276
- Aspirin
 - for antiphospholipid antibody-related infertility, 29
 - for antiphospholipid syndrome during pregnancy, 20
 - in women with low levels of antibodies, 20
 - for prevention of pregnancy loss, in classic (definite) antiphospholipid syndrome, 20
- Assisted reproductive technology, outcomes for, uterine leiomyomas and, 364, 385
- Association of Official Agricultural Chemists, dietary supplements task force, 789
- Ataxia-telangiectasia (AT), genetics of, 450
- Atherosclerosis, garlic for, 814
- ATM gene, mutations, and hereditary breast cancer, 450
- Atrophic vaginitis, estriol for, 864
- Atypical squamous cells of undetermined significance (ASCUS), 538
- Auricular therapy, 681

- Autocyte cervical cancer screening, 538
 Autohypnosis, 704
 Autoimmune hemolytic anemia, in pediatric AIDS, 243
 Autonomy, ethical principle of, 300
 AutoPap, 538
 AZT. *See* Zidovudine
- B**
 Bacterial infection(s)
 in pediatric AIDS, 243
 as presenting HIV-related condition, 167
 Bacterial vaginosis
 in HIV-infected (AIDS) patients
 epidemiology of, 226
 pathology of, 226
 and HIV shedding, in female genital tract, 144, 226
 Bannayan-Zonana syndrome, 335
 Barium enema, in gynecologic oncology, 485
bcl-2 protein, in uterine leiomyomas, 327
 Bendectin, 653
 Beta-carotene, Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 Bethesda System, for Pap smear interpretation, 538
 Biest, 864
 Bioelectromagnetics, 640. *See also* Electroacupuncture;
 Transcutaneous electrical nerve stimulation (TENS)
 definition of, 704
 Biofeedback
 definition of, 681
 in labor and delivery, 681, 704
 Black cohosh, 681
 Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
 for menopausal symptoms, 853
 pharmacologic properties of, 853
 Bladder, uterine leiomyomas and, 364, 385
 Bleeding
 abnormal vaginal, with uterine leiomyomas, 364, 385
 breakthrough, with oral contraceptives, 62
 with chronic anticoagulation, 36
 hormone replacement therapy and, 853
 Blood, as vital substance, in traditional Chinese medicine, 801
 Blood loss, intraoperative
 in hysterectomy, 385
 in myomectomy, 385
 limiting, 385
 Blood pressure. *See also* Hypertension
 garlic and, 814
 injectable long-acting contraceptives and, 73
 Blue cohosh, 681, 853
 Body fluids, as vital substances, in traditional Chinese medicine, 801
 Body mass index (BMI), and uterine leiomyomas, 316
 Bone
 loss, postmenopausal
 hormone replacement therapy and, 464, 836, 864
 phytoestrogens and, 836, 843
 rate of, 464
 metabolism, dehydroepiandrosterone and, 880
 Bone mineral density
 Depo-Provera and, 73
 estriol and, 864
 estrogen replacement therapy and, 864
 heparin and, 36
 hormone replacement therapy and, 464, 836, 864
 improvement in, oral contraceptives and, 62
 phytoestrogens and, 836, 843
 Bone radiography, in gynecologic oncology, 485
 Bone scans, in gynecologic oncology, 485
 Botanicals. *See also* Herbal medicine; Phytoestrogens
 in cardiovascular health, 814
 and central nervous system, 824
 definition of, 853
 efficacy testing, methods validation problem and, 789
 Institute for Nutraceutical Advancement (INA) Methods Validation Program for, 789
 marker compounds in, 789
 and menopausal vasomotor symptoms, 836, 853
 for menopause, 853
 quality assurance, methods validation problem and, 789
 safety assessment, methods validation problem and, 789
 self-regulation of, methods validation problem and, 789
 Bovine spongiform encephalopathy
 dietary supplements and, 789
 dong quai and, 853
 Brachytherapy, for cervical cancer, 531
BRC11 gene, mutations
 and breast cancer, 478
 commercial testing for, 450
 and hereditary breast and ovarian cancer, 450
 and ovarian cancer risk, 450
 and prostate cancer, 450
BRC12 gene, mutations
 and breast cancer, 478
 commercial testing for, 450
 and hereditary breast and ovarian cancer, 450
 and pancreatic cancer, 450
 and prostate cancer, 450
 Breast, estriol and, 864
 Breast cancer. *See also* Hereditary breast and ovarian cancer
 androgens and, 880
 chemoprevention of, 478
 CYP19 polymorphism and, 450
 epidemiology of, 478
 estriol and, 864
 hereditary, genetics of, 478
 in hereditary nonpolyposis colorectal cancer syndrome, 450
 in HIV-infected (AIDS) patients, 167
 prevention of, 478
 lifestyle changes for, 478
 soy phytoestrogens in, 836, 843
 risk
 calculation of, Gail model for, 478
 estrogens and, 450, 864
 hormone replacement therapy and, 464, 853, 864
 injectable long-acting contraceptives and, 73
 oral contraceptives and, 62

- single nucleotide polymorphisms and, 450
- survivors, hormone replacement therapy in, 464
- Breast disease, benign, decreased incidence of, oral contraceptives and, 62
- Breastfeeding
 - and breast cancer prevention, 478
 - doula-supported mothers and, 692
 - HIV transmission in, 198, 210, 243
- Breast tenderness, with oral contraceptives, 62
- Breech presentation
 - and risk of uterine rupture during trial of labor, 588, 609
 - uterine leiomyomas and, 364
 - and vaginal birth after cesarean delivery, 588
- Budd-Chiari syndrome
 - in antiphospholipid syndrome, 36
 - with malignancy, 36
- C**
- CA-125, serum, measurement of
 - in ovarian cancer diagnosis, 495, 522
 - in ovarian cancer surveillance, 450, 495, 522
 - in ovarian cancer survivors, 485
- Cancer
 - BRCA* gene mutations and, 450
 - dehydroepiandrosterone and, 880
 - gynecologic
 - laparoscopic procedures for, and port site metastases, 495
 - staging of, 485
 - laparoscopy in, 495
 - hereditary, 450. *See also* Hereditary breast and ovarian cancer: Hereditary nonpolyposis colorectal cancer (HNPCC)
 - chemoprevention of, 450
 - clinical hallmarks of, 450
 - genetics of, 450
 - patient counseling about, 450
 - penetrance estimates for, 450
 - surgical prophylaxis for, 450
 - surveillance for, 450
 - protection against, soy phytoestrogens and, 836, 843
 - survivors, hormone replacement therapy in, 464
- Candida* esophagitis
 - in HIV-infected (AIDS) patients, 167
 - in pediatric AIDS, 243
- Candida* vulvovaginitis
 - in HIV-infected (AIDS) patients, management of, 167
 - as presenting HIV-related condition, 167
- Candidiasis
 - in HIV-infected (AIDS) patients, management of, in pregnancy, 182
 - oral, as presenting HIV-related condition, 167
 - vaginal, in HIV-infected (AIDS) patients, 226
- Capronor, 92
- Carboplatin, for ovarian cancer, 522
- Carcinoma, uterine, 350
- Cardiovascular disease
 - dehydroepiandrosterone and, 880
 - estrogens and, 843, 864
 - garlic for, 814
 - hawthorn for, 814
 - oral contraceptives and, 62
 - protection against
 - hormone replacement therapy and, 464, 843, 864
 - phytoestrogens and, 843
 - risk factors for, injectable long-acting contraceptives and, 73
- Cardiovascular events, injectable long-acting contraceptives and, 73
- Caulophyllum thalictroides*. *See* Blue cohosh
- CCR5 β -chemokine receptor
 - D32 mutation, and resistance to HIV-1, 137, 198
 - in HIV-1 infection, 137
- CD4 receptor, in HIV-1 infection, 137
- Cellulose, oxidized regenerated, 401
- Central nervous system
 - herbs affecting, 824
 - in pediatric AIDS, 243
- Cephalopelvic disproportion, previous cesarean delivery for, and vaginal birth after cesarean delivery, 561
- Cerebral ischemia
 - in antiphospholipid syndrome, 36
 - oral contraceptives and, 62
- Cerebral palsy, 571
- Cerebrovascular disease, risk, hormone replacement therapy and, 464
- Cervical cancer
 - follow-up for, 485
 - in HIV-infected (AIDS) patients, 167, 226
 - invasive, management of, 531
 - laparoscopic procedures for, and port site metastases, 495
 - management of
 - brachytherapy for, 531
 - cisplatin for, 531
 - combine chemo/radiation for, 531
 - radiation therapy for, 531
 - metastases of
 - detection of, 485
 - management of, 485
 - missed diagnosis of, 538
 - mortality rate for, 538
 - radiographic imaging in, 485
 - risk, injectable long-acting contraceptives and, 73
 - screening for, 538
 - computer-assisted, 538
 - efficacy of, 538
 - failure of, reasons for, 538
 - fluorescence spectroscopy in, 538
 - human papillomavirus (HPV) testing and, 538
 - liquid-based cytology for, 538
 - methods for, 538
 - sentinel lymph node detection in, 531
 - stage I, management of, 531
 - stage IB2, management of, 531
 - stage IIA, management of, 531
 - staging of, 485
 - laparoscopic, 495
 - ureteral obstruction with, evaluation of, 485
- Cervical intraepithelial lesions
 - high-grade, detection of, 538
 - low-grade, detection of, 538
- Cervical intraepithelial neoplasia, in HIV-infected (AIDS) patients, 226
- Cervical ripening, outpatient, after previous cesarean delivery, 622

- Cesarean delivery. *See also* Vaginal birth after cesarean delivery
- analgesia after, transcutaneous electrical nerve stimulation (TENS) for, 704
 - analgesia for, acupuncture in, 681
 - controversy about, 553, 561
 - economics of, 552
 - elective repeat, 553
 - informed consent for, 622
 - versus trial of labor, 594
 - emergency response time for, and VBAC, 561, 622
 - historical perspective on, 553, 561
 - maternal age and, 553
 - maternal mortality rate for
 - causes of, 553
 - historical trend in, 553
 - National Institutes of Health (NIH) report on, 561
 - number of, and risk of uterine rupture during trial of labor, 609, 622
 - outcomes with, 553
 - in HIV-infected (AIDS) patients, 154
 - and prevention of vertical transmission of HIV, 198, 210, 243
 - rate of
 - in Europe, 594, 604
 - in United States, 552, 561, 594, 604
 - factors affecting, 553
 - target for, 553
 - trend in, 553
 - repeat
 - morbidity of, 561
 - rate of, 604
 - in Europe, 594
 - in United States, 561, 594
 - safety of, 604
 - scar type, and risk of uterine rupture during trial of labor, 609, 622
 - uterine leiomyomas and, 364
 - and vaginal delivery, relative morbidity of, 553
- Cesarean delivery [term], origin of, 553
- Cetorelix, for uterine leiomyomas, 372
- Chakra(s), 750
- Chancroid
 - in HIV-infected (AIDS) patients, management of, 226
 - interactions with HIV, 226
- Chasteberry, for menopausal symptoms, 853
- Chemoprevention
 - of breast cancer, 478
 - of hereditary cancer, 450
- Chemotherapy
 - for cervical cancer, 531
 - for ovarian cancer, 522
 - in disease recurrence, 522
- Chest x-rays, in gynecologic oncology, 485
- Childbirth. *See also* Home birth
- attendants at. *See also* Doula(s); Midwifery
 - historical perspective on, 692
 - father-supported, 692
 - holistic approach to, 671
 - Native Americans and, 661
 - pain relief in. *See* Pain relief, in labor and delivery
 - safety of, in United States, 553
 - stress response in, 692
 - technocratic approach to, 671
 - traditional Chinese medicine and, 801
 - in water, 733. *See also* Hydrotherapy
- Children, HIV infection in. *See* Pediatric AIDS
- Chinese ginseng. *See* Ginseng
- Chinese medicine, traditional. *See also* Acupuncture
- and conception, 801
 - disease in
 - causes of, 801
 - diet and, 801
 - emotional stresses and, 801
 - excessive physical work or exercise and, 801
 - excessive sexual activity and, 801
 - oral contraceptives and, 801
 - exterior pathogenic factors in, 801
 - herbal medicine in, 801
 - historical perspective on, 801
 - internal organs in, 801
 - meditation in, 801
 - and menopause, 801
 - mind/body interventions in, 801
 - pregnancy and childbirth in, 801
 - surgery and hysterectomy in, 801
 - vital substances in, 801
 - women's physiology in, 801
- Chi (Qi), 681, 704, 750
 - in traditional Chinese medicine, 801
- Chiropractic pediatrics, 750
- Chlamydia* cervicitis, in HIV-infected (AIDS) patients, 167
- Chlamydia* infection
 - interactions with HIV, 226
 - and uterine leiomyomas, 316
- Chlorhexidine, 210
- Cholesterol, serum levels, soy isoflavones and, 836
- Chondroitin sulfate
 - Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 - and bovine spongiform encephalopathy, 789
- Choriocarcinoma, gestational, 485
- Chorionic villus sampling, Native Americans and, 661
- Chromosomal abnormalities, in leiomyomata uteri, 335, 385
 - del(7)(q22q32) subgroup of, 335
 - 6p21 subgroup of, 335
 - t(12;14) subgroup of, 335
- Chromosome 3, abnormalities, and uterine leiomyomas, 335
- Chromosome 7, abnormalities, and uterine leiomyomas, 335
- Chromosome 10, abnormalities, and uterine leiomyomas, 335
- Chromosome 13, abnormalities, and uterine leiomyomas, 335
- Cimicifuga racemosa*. *See* Black cohosh
- Cisplatin
 - for cervical cancer, 531
 - for ovarian cancer, 522
- Clonality, of uterine leiomyomas, 335
- Coagulation, injectable long-acting contraceptives and, 73
- Coccidioides immitis* infection, in HIV-infected (AIDS) patients, management of, in pregnancy, 182
- Co-enzyme Q10, Association of Official Agricultural Chemists' task force on dietary supplements and, 789
- Cognitive function

- ginkgo and, 824
- growth hormone and, 893
- soy phytoestrogens and, 843
- Cognitive symptoms, menopausal, hormone replacement therapy and, 464
- Collagen, metabolism of, and uterine leiomyomas, 316
- Colorectal cancer. *See also* Hereditary nonpolyposis colorectal cancer (HNPCC)
 - prevention of, hormone replacement therapy in, 464
 - risk, reduced, oral contraceptives and, 62
 - single nucleotide polymorphisms and, 450
- Color therapy, in neonatal intensive care unit, 750
- Combivir, for pediatric AIDS, 243
- Comparative estrogenology, 864
- Complementary and alternative medicine
 - classification of, 774
 - clinical programs in, 774
 - cost of, 640
 - criticisms of, 640
 - definition of, 640, 681, 704, 774
 - efficacy of, 640
 - clinical trial evidence of, 902
 - mechanisms of, 640
 - ethical considerations with, 640
 - for pain relief in labor and delivery, 704
 - expenditures for, 704
 - insurance coverage for, 774
 - integration into clinical practice, 902
 - interference with conventional medicine, 640
 - Internet resources on, 902
 - licensure of health professionals in, 640
 - literature on, 640
 - malpractice considerations with, 640
 - medical education and, 774
 - medical professionals' attitudes toward, 774
 - for morning sickness, 653
 - in neonatal intensive care unit, 750
 - nursing care and, 750
 - rationale for, 750
 - newsletters on, 902
 - in obstetrics, 639
 - for pain relief in labor and delivery
 - ethical considerations in, 704
 - legal considerations in, 704
 - research on, 704
 - techniques used for, 704
 - popularity of, 640, 704, 774
 - in pregnancy
 - demographics of, 681
 - literature on, 681
 - professional training opportunities in, 902
 - references on, 902
 - referrals for, 640, 704
 - research on, 640, 774
 - resources on, for practitioners, 902
 - self-referral for, 640, 704
 - spectrum of therapies in, 640
 - talking to patients about, 902
 - use of
 - extent of, 640
 - in pregnancy, demographics of, 681
 - prevalence of, 774
 - trends in, 704
 - users of
 - characteristics of, 640, 704, 774
 - rationale of, 640, 774
- Complementary medicine. *See also* Complementary and alternative medicine
 - definition of, 640
- Computed tomography (CT), in gynecologic oncology, 485
- Conception, traditional Chinese medicine and, 801
- Condom use
 - by adolescents, 114
 - by HIV-infected women, 226, 289
 - antiretroviral therapy and, 289
 - negotiation of, with partners, 289
- Confidentiality, of HIV-infected (AIDS) patients, 300
- Connective tissue, metabolism of, and uterine leiomyomas, 316
- Consumer Health Products Association, and labeling requirements for dietary supplements, 789
- Consumerism, and complementary and alternative medicine, 704
- ConsumerLab, testing of herbal medicines and dietary supplements, 789
- Contraception
 - for adolescents, 114
 - emergency, 114
 - emergency, 101
 - adolescents' use of, 114
 - for HIV-infected (AIDS) patients, 182, 226, 289
 - postcoital, 101
 - contraindication to, 101
 - danazol for, 101
 - estrogens for, 101
 - intrauterine device for, 101
 - mechanism of action of, 101
 - methods for, 101
 - oral contraceptives for, 101
 - reasons to consider, 101
 - RU486 for, 101
 - and uterine leiomyomas, 316
 - vaginal ring hormone delivery system in, 106
- Contraceptives. *See also* Oral contraceptives
 - comparisons of, 73
 - implantable, 92. *See also* Norplant
 - advantages and disadvantages of, 92
 - adverse effects and side effects of, 92
 - biodegradable pellets for, 92
 - candidates for, 92
 - comparison with other contraceptive methods, 73
 - continuation rates with, 92
 - contraindications to, 92
 - efficacy of, 92
 - historical perspective on, 92
 - insertion of, 92
 - mechanism of action of, 92
 - public health concerns with, 92
 - removal of, 92
 - injectable, and uterine leiomyomas, 316
 - injectable long-acting, 73
 - comparison with other contraceptive methods, 73
 - continuation of, physician's role in, 73
- Corticosteroids, for antiphospholipid antibody-related infertility, 29

- Cost analysis
 application of, 571
 construction of, 571
 denominator issues in, 571
 discounting in, 571
 numerator issues in, 571
 reference case for, 571
 societal perspective for, 571
 types of, 571
 uncertainty and, 571
 of vaginal birth after cesarean delivery, 571
- Cost-benefit analysis, 571
- Cost-effectiveness analysis, 571
 of vaginal birth after cesarean delivery, 571
- Cost-minimization analysis, 571
- Cost-utility analysis, 571
- Coumestans, as phytoestrogens, 836
- Counseling
 for patients at high risk of hereditary cancer, 450
 for pregnant HIV-infected (AIDS) patient, 300
- Counter-irritation. *See also* Sterile water blocks
 definition of, 704
- Cowden disease, 335
- Cowden syndrome, genetics of, 450
- Cragin, Edward, 'Once a Cesarean, always a Cesarean'
 dictum of, 553, 561, 594, 604
- Crataegus* spp. *See* Hawthorn
- Creutzfeldt-Jakob disease. *See* Bovine spongiform encephalopathy
- Crixivan. *See* Indinavir
- Cryomyolysis, laparoscopic, 401
- Cryptococcus neoformans* meningoencephalitis, in HIV-infected (AIDS) patients, management of, in pregnancy, 182
- Cultural competency, in health care, 661
- CXCR4 chemokine receptor, in HIV-1 infection, 137
- Cytochrome P-450, St. John's wort and, 824
- Cytokines
 cervicovaginal levels of
 in HIV-infected (AIDS) patients, 144
 menstrual cycle and, 144
 and HIV expression, 144
- Cytomegalovirus (CMV) infection
 in HIV-infected (AIDS) patients, management of, in pregnancy, 182
- in pediatric AIDS, 243
- Cytotec. *See* Misoprostol
- D
- Daidzein. *See* Diadzein
- Danazol
 for postcoital contraception, 101
 for uterine leiomyomas, 372
- DC-SIGN, HIV binding by, 144
- ddC. *See* Zalcitabine
- ddl. *See* Didanosine
- Deep venous thrombosis
 in antiphospholipid syndrome, 36
 hormone replacement therapy and, 36
 oral contraceptives and, 36
 tamoxifen-related, 478
 uterine artery embolization for myomas and, 412
- Dehydroepiandrosterone (DHEA)
 adverse effects and side effects of, 880
 and bone metabolism, 880
 and brain function, 880
 and cancer, 880
 and cardiovascular disease, 880
 clinical trials of, 880
 immune effects of, 880
 metabolic effects of, 880
 over-the-counter, 880
- Dehydroepiandrosterone sulfate (DHEAS), over-the-counter, 880
- Delavirdine, 243
 use in pregnancy, preclinical and clinical data relevant to, 182
- Delivery route, and risk of vertical transmission of HIV, 198, 210
- Depo-Provera
 adolescents' use of, 114
 adverse effects and side effects of, 73
 and bone density, 73
 comparison with other contraceptive methods, 73
 concomitant medication use and, 73
 continuation of, physician's role in, 73
 contraceptive efficacy of, 73
 contraindications to, 73
 discontinuation of, return to fertility after, 73
 formulation of, 73
 inadvertent administration during pregnancy, 73
 initial and subsequent injections, timing of, 73
 mechanism of action of, 73
 menstrual changes with, 73
 noncontraceptive benefits of, 73
 pharmacology of, 73
 therapeutic uses of, 73
 weight changes with, 73
- Depression
 with injectable long-acting contraceptives, 73
 St. John's wort for, 824
- Desogestrel, in oral contraceptives, 62
- Dextran sulfate, in prevention of HIV transmission, 226
- Diabetes mellitus
 and myocardial infarction risk, 62
 and uterine leiomyomas, 316
- Diadzein, 836, 843
- Diadzin, 836
- Didanosine
 for pediatric AIDS, 243
 in prevention of vertical transmission of HIV, 210
 use in pregnancy
 long-term effects of, 182
 preclinical and clinical data relevant to, 182
- Diet
 and breast cancer prevention, 478
 and disease, in Chinese medicine, 801
 and uterine leiomyomas, 316
- Dietary Supplement Health and Education Act, 780, 789
- Dietary supplements
 adulterated, 780
 adverse events caused by, reporting, 780
 Association of Official Agricultural Chemists' task force on, 789
 benefits of, 780
 and bovine spongiform encephalopathy, 789
 claims permissible on, 780
 definition of, 780

- versus drugs, 780
- efficacy of, 780
 - clinical trial evidence of, 902
- efficacy testing, methods validation problem and, 789
- federal regulation of, 640, 780, 789
- Good Manufacturing Practices for, 789
 - National Nutritional Foods Association and, 789
- labeling requirements for, 780, 789
- manufacturing of, 780
 - industry self-regulation of, 789
- popularity of, 780, 789
- precautions with, 780
- quality controls and, 780, 789
 - methods validation problem and, 789
- research on, 789
- risks of, 780
- safety of, 780, 789
 - assessment, methods validation problem and, 789
- testing of
 - by ConsumerLab, 789
 - by National Nutritional Foods Association, 789
 - third-party literature on, 780
 - use of, physician's role in, 780
- Diet therapy, 640
- Dihydrokavain, 824
- Dihydromethysticin, 824
- Dioscorea villosa*. *See* Wild yam creams
- Distant intentionality, and neonatal healing, 750
- DNA (deoxyribonucleic acid)
 - cloning of, 425
 - delivery to cells, in gene therapy, 425
 - direct injection of, in gene therapy, 425
 - mismatch repair, 450
- Dong quai
 - adverse effects and side effects of, 853
 - and bovine spongiform encephalopathy, 853
 - drug interactions with, 853
 - for menstrual symptoms, 853
- Doula(s)
 - beneficial effects of, 692
 - certification of, 692
 - compensation for, 692
 - definition of, 692
 - and father-supported childbirth, 692
 - historical perspective on, 692
 - neonatal benefits of, 692
 - postpartum benefits of, 692
 - support techniques used by, 692
 - training of, 692
- d4T. *See* Stavudine
- Dysmenorrhea, depot medroxyprogesterone acetate for, 73
- Dyspareunia, with uterine leiomyomas, 385
- Dystocia, previous cesarean delivery for, and vaginal birth after cesarean delivery, 561
- Dysuria, estriol for, 864
- E
- Echinacea, Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
- Ectopic pregnancy, protection against, oral contraceptives and, 62
- Efavirenz
 - for pediatric AIDS, 243
 - teratogenicity of, 182
 - use in pregnancy, preclinical and clinical data relevant to, 182
- EGb 761, 814, 824
- Eicosanoids, and pregnancy loss in antiphospholipid syndrome, 11, 20
- Elderly, dehydroepiandrosterone for, and improvements in well-being, 880
- Electroacupuncture
 - complications of, 704
 - definition of, 681
 - for labor analgesia, 704
 - for labor induction, 681
- Eleuthera (Siberian) ginseng. *See* Ginseng
- Embryo transfer, pregnancy rates with, uterine leiomyomas and, 364
- Endometrial biopsy, indications for, 412
- Endometrial cancer
 - depth of invasion by, evaluation of, 485
 - estrogen and, 464, 864
 - in hereditary nonpolyposis colorectal cancer syndrome, 450
 - laparoscopic procedures for, and port site metastases, 495
 - metastases, risk factors for, 485
 - prevention of
 - progestins in, 864
 - soy phytoestrogens in, 843
 - radiographic imaging in, 485
 - risk. *See* Endometrial cancer risk
 - staging of, 485
 - laparoscopic, 495
 - survivors, hormone replacement therapy in, 464
- Endometrial cancer risk
 - hormone replacement therapy and, 464
 - reduced
 - depot medroxyprogesterone acetate and, 73
 - oral contraceptives and, 62
 - soy phytoestrogens and, 843
 - tamoxifen-related, 478
- Endometriosis, management of, depot medroxyprogesterone acetate for, 73
- Endometrium
 - androgens and, 880
 - estriol and, 864
 - histology of, uterine leiomyomas and, 364
 - resection and ablation, for uterine leiomyomas, 412
 - sarcoma of, poorly differentiated, 350
 - stromal tumors of, differential diagnosis of, 350
 - vascular flow in, uterine leiomyomas and, 364
- Endothelial cells, antiphospholipid antibodies and, 11, 20
- Energy-based healing, 750. *See also* Touch, therapeutic
- Energy workers, and neonatal healing, 750
- Enoxaparin, for thrombosis in antiphospholipid syndrome, 36
 - nomogram for, 36
- Enzyme-linked immunosorbent assay
 - for anticardiolipin antibodies, 36
 - positive results on, disorders causing, 48
 - for HIV detection, 167

- Ephedra alkaloids
 Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 labeling of, 789
 Ephivir. *See* Lamivudine
 Equol, 836
 Escin, 814
 Essence, as vital substance, in traditional Chinese medicine, 801
 Essential oils, 704
 Estimated date of delivery, gestation beyond, and risk of uterine rupture during trial of labor, 609
 Estradiol, 864
 Estratest, 880
 Estriol
 biochemistry of, 864
 branded products, 864
 and breast, 864
 and breast cancer, 864
 clinical applications of, 864
 and endometrium, 864
 lipid effects of, 864
 tissue/plasma gradients of, 864
 topical, 864
 Estrogen
 conjugated equine, 864
 exogenous
 benefits of, 864
 contraindications to, 864
 formulations, pharmacologic properties of, 864
 and growth of uterine leiomyomas, 372
 natural, 864
 oral preparations, relative biological potency of, 864
 plant. *See* Phytoestrogens
 plant-derived, 864
 for postcoital contraception, 101
 unconventional, 864
 Estrogenology, comparative, 864
 Estrogen/progestin combination, vaginal ring delivery system for, 106
 Estrogen receptor modulators, for uterine leiomyomas, 372
 Estrogen replacement therapy. *See also* Hormone replacement therapy (HRT)
 benefits of, evidence-based, 864
 in cancer survivors, 464
 and cognitive function, 464
 conventional, estriol and, comparison of, 864
 dosing equivalents of, 464
 and endometrial cancer risk, 464
 and ERT plus methyltestosterone, comparison of, 880
 formulations for, 864
 and phytoestrogens, comparison of, 843, 853
 protective effect against breast cancer, in *BRCA* gene mutation carriers, 450
 Estrone, 864
 Estroven, 853
 Ethical issues
 in alternative therapies for pain in labor, 704
 in care of HIV-infected (AIDS) patients, 300
 in complementary and alternative medicine, 640
 Ethnic populations, and hereditary breast cancer, 450
 Etonogestrel
 combinations, vaginal ring delivery system for, 106
 vaginal ring delivery system for, 106
 Evening primrose
 indications for, 853
 for menopausal symptoms, 853
 Evidence, quality of, 588
 Exercise, and breast cancer prevention, 478
 External cephalic version, and risk of uterine rupture during trial of labor, 588, 609
- F
 Factor V Leyden, 62
 Fallopian tube(s), occlusion of, by uterine leiomyomas, 364
 Familial leiomyomatosis cutis and uteri, 335
 Family history
 in cancer risk stratification, 450
 and uterine leiomyomas, 316
 Febrile morbidity
 after previous cesarean delivery, and risk of uterine rupture during trial of labor, 609
 neonatal, 571
 postpartum, 571
 Fertility
 after laparoscopic myomectomy, 401
 after myomectomy, 385
 after uterine artery embolization for myomas, 412
 HIV infection and, 154
 return to, after use of injectable long-acting contraceptives, 73
 Fetal distress, in antiphospholipid syndrome, 2
 Fetal growth impairment, in antiphospholipid syndrome, 2
 Fetal loss. *See also* Pregnancy loss
 in antiphospholipid syndrome, 11
 placental histopathology with, 11
 Fetal mortality, 571
 Feverfew, potential detrimental effects of, 640
 Fibroblastic growth factor, basic, in uterine leiomyomas, 372
 Fibroids. *See* Leiomyomata uteri
 Fibromas, uterine. *See* Leiomyomata uteri
 Fibromyomas, uterine. *See* Leiomyomata uteri
 Fibrotic disease
 transforming growth factor β in, 327
 uterine leiomyomas as, 327
 Fluorescence spectroscopy, in cervical cancer screening, 538
 Food and Drug Administration (FDA)
 and acupuncture, 801
 and dietary supplements, 780, 789
 Good Manufacturing Practices for dietary supplements, 789
 regulation of alternative therapies, 640
 Fortovase. *See* Saquinavir
 Fracture(s), postmenopausal, 464
 Fungal infection(s), in HIV-infected (AIDS) patients, 243
- G
 Gail model, for breast cancer risk calculation, 478
 Garlic
 in cardiovascular health, 814
 hypotensive effect of, 814

- Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
 pharmacologic properties of, 814
- Gastrointestinal symptoms
 in pediatric AIDS, 243
 with uterine leiomyomas, 385
- Gelatin, and bovine spongiform encephalopathy, 789
- Gene therapy
 corrective, 425
 cytotoxic, 425
 for uterine leiomyomas, 425
 gene transfer for
 by direct injection, 425
 nonviral, 425
 viral, 425
 human trials of, 425
 immunologic, 425
 principles of, 425
 strategies for, 425
 and uterine leiomyomas, 425
- Genetic counseling, for cancer risk, 450
- Genetic testing
 for hereditary cancer syndromes, 450
 informed consent for, 450
 limitations of, 450
 psychological distress caused by, 450
- Gene transfer, in gene therapy, 425
 nonviral, 425
 viral, 425
- Genistein, 836, 843
- Genistin, 836
- Genitourinary atrophy, menopausal, hormone replacement therapy and, 464
- Genome-wide screen, 335
- Gestational trophoblastic disease, radiographic imaging in, 485
- Gestational trophoblastic tumors, malignant
 diagnosis of, 485
 follow-up for, 485
 imaging of, 485
 metastases, detection of, 485
- Gestrinone, for uterine leiomyomas, 372
- Ginger
 Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
 for morning sickness, 653
- Ginkai, 814
- Ginkgo biloba
 Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 in cardiovascular health, 814
 central nervous system effects of, 824
 extract (GBE), 814, 824
 adverse effects and side effects of, 814, 824
 constituents of, 824
 drug interactions with, 824
 pharmacologic properties of, 824
 Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
 potential detrimental effects of, 640
- Ginseng
 as adaptogen, 853
 American, 853
 Association of Official Agricultural Chemists' task force on dietary supplements and, 789
- Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
 Chinese, 853
 clinical effects of, research on, 853
 eleuthera (Siberian), Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 for menstrual symptoms, 853
 Siberian, 853
- Glucosamine, Association of Official Agricultural Chemists' task force on dietary supplements and, 789
- Glycesterone, 853
- Glycosaminoglycans, and pregnancy loss in antiphospholipid syndrome, 11
- Glycyrrhiza glabra*. See Licorice
- Gonadotropin-releasing hormone (GnRH) agonists. See Gonadotropin-releasing hormone (GnRH) analogs
- Gonadotropin-releasing hormone (GnRH) analogs
 adverse effects and side effects of, 401
 for uterine leiomyomas, 372. *See also* Leuprolide acetate therapy
 and add-back therapy, 372
 adverse effects and side effects of, 385
 drawbacks of, 412, 425
 efficacy of, 385
 and myoma recurrence after myomectomy, 385
 preoperative therapy with, 385, 401
 response to, evaluation of, 385
- Gonadotropin-releasing hormone (GnRH) antagonists
 mechanism of action of, 372
 for uterine leiomyomas, 372
- Gonorrhea, interactions with HIV, 226
- Good Manufacturing Practices
 for dietary supplements, 789
 US Pharmacopeia's, 789
- Green tea, Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
- Growth, somatic, pediatric AIDS and, 243
- Growth factor(s)
 angiogenic, in uterine leiomyomas, 327, 372
 in uterine leiomyomas, 327
- Growth hormone (GH)
 and aerobic capacity, 893
 and body composition, 893
 cognitive effects of, 893
 exogenous, adverse effects and side effects of, 893
 immune effects of, 893
 metabolic effects of, 893
 physiology of, in adults, 893
 precursors, over-the-counter, 893
 recombinant human
 adverse effects and side effects of, 893
 in aging, 893
 benefits of, 893
 secretagogues
 Internet resource on, 893
 sold as health food supplements, 893
 use of, in aging, 893
 secretion, age-related changes in, 893
 skeletal effects of, 893
 and strength, 893
 use of, in aging, 893

- Growth hormone-releasing hormone (GHRH)
 exogenous, 893
 physiology of, 893
 Growth hormone Stak Pro-HGH-Symbiotropin, 893
 Gynecologic care, for HIV-infected (AIDS) patients, 226
 Gynecologic Oncology Group (GOG), clinical trials of
 therapy for advanced cervical cancer, 531
- H
- Halofuginone, therapeutic potential of, for uterine leiomyomas, 327
- Hawthorn
 in cardiovascular health, 814
 commercial extracts
 constituents of, 814
 LI 132 (Faros), 814
 WS 1442 (Crataegutt), 814
- HCSE, 814
- Headache, with implantable contraceptives, 92
- Healing touch. *See* Touch, therapeutic
- Heart, in traditional Chinese medicine, 801
- Heart disease
 hawthorn for, 814
 in pediatric AIDS, 243
- Helicobacter pylori*, and hyperemesis gravidarum, 653
- Heparin
 for antiphospholipid antibody-related infertility, 29
 for antiphospholipid syndrome during pregnancy, 20
 in women with low levels of antibodies, 20
 low-molecular-weight
 complications of therapy with, 36
 dose titration, nomogram for, 36
 in pregnancy, 36
 for thrombosis in antiphospholipid syndrome, 36
 for prevention of pregnancy loss, in classic (definite) antiphospholipid syndrome, 20
 therapeutic potential of, for uterine leiomyomas, 327
 for thromboprophylaxis, in classic (definite) antiphospholipid syndrome, 20
 unfractionated intravenous
 complications of therapy with, 36
 for thrombosis in antiphospholipid syndrome, 36
- Heparin-binding growth factors
 inhibitors of, therapeutic potential for uterine leiomyomas, 327
 in uterine leiomyomas, 327
- Hepatitis B, risk of, use of water in labor and birth and, 733
- Hepatitis C, risk of, use of water in labor and birth and, 733
- Herbalism. *See* Herbal medicine
- Herbal medicine. *See also* Botanicals; Phytoestrogens
 Chinese, 681
 efficacy of, clinical trial evidence of, 902
 in labor analgesia, 704
 in labor and delivery, 681
 and neonatal healing, 750
 obstetrical, use by Native Americans, 661
 precautions with, in pregnancy, 704
 product labeling issues in, 789
 sources of remedies in, 681
 in traditional Chinese medicine, 801
 use by Native Americans, 661
 use of, extent of, 750
- Hereditary breast and ovarian cancer, 450
 genetics of, 450
- Hereditary nonpolyposis colorectal cancer (HNPCC), 450
 cancer types found in, 450
 diagnostic criteria for, 450
 genetics of, 450
- Herpes simplex virus (HSV)
 genital ulcers, in HIV-infected (AIDS) patients, 167
 management of, in pregnancy, 182
 in HIV-infected (AIDS) patients, management of, 226
 interactions with HIV, 226
 oral ulcers, in HIV-infected (AIDS) patients, management of, in pregnancy, 182
 thymidine kinase gene, in cytotoxic gene therapy, 425
 as vector for gene therapy, 425
- Herpes zoster, as presenting HIV-related condition, 167
- Highly active antiretroviral therapy (HAART)
 adverse effects and side effects of, 243
 and cervicovaginal levels of HIV, 144
 efficacy of, 154
 and HIV-1 level, 137
 for pediatric AIDS, 243
 in pregnancy, 210
 benefits of, 154
 research on, advances in (future directions for), 210
 risks of, 154
 studies of, advances in (future directions for), 154
 and sexual risk behavior by HIV-infected women, 289
- High mobility group proteins, 335
- Hip fractures, postmenopausal, 464
- Histochemistry, of uterine tumors, 350
- Histoplasmosis, in HIV-infected (AIDS) patients, management of, in pregnancy, 182
- HIV-1. *See* Human immunodeficiency virus 1 (HIV-1)/infection
- HIV-2. *See* Human immunodeficiency virus 2 (HIV-2)
- HIVID. *See* Zalcitabine
- HIV-inducing factor (HIF), 144
- HMG17* gene, 335
- HMGIC* gene, 335
- HMG1Y* gene, 335
- Home birth
 ACOG policy statement on, 671
 attendants at, 671
 demographics of, 671
 historical perspective on, 671
 intrapartum transfer and, 671
 mortality rates with, 671
 national and state studies of, 671
 outcome studies of, 671
 planned *versus* unplanned, 671
 rationales for, 671
 safety of, 671
 screening and, 671
 trends in, 671
- Homeopathy
 historical perspective on, 681
 and neonatal healing, 750
 principles of, 681, 750
 regulation of, 640
 sources of remedies in, 681
- Hormonal therapy, vaginal ring delivery system for, 106
- Hormone(s)
 and cervicovaginal levels of HIV, 144
 in HIV-infected (AIDS) patients, 167

- Hormone replacement therapy (HRT). *See also* Estrogen replacement therapy
- adverse effects and side effects of, 853
 - benefits of, 464
 - bleeding with, 464
 - and bone mineral density, 836, 864
 - in breast cancer patients, 464
 - and breast cancer risk, 464, 864
 - in cancer survivors, 464
 - cardioprotective effect of, 464, 864
 - cerebrovascular disease risk with, 464
 - and colorectal cancer prevention, 464
 - compliance with, 464
 - contraindications to, 464
 - dosage and administration of, 464
 - in endometrial cancer patients, 464
 - endometrial cancer risk with, 464
 - estriol and, comparison of, 864
 - and osteoporosis prevention, 464
 - in ovarian cancer patients, 464
 - ovarian cancer risk with, 464
 - and phytoestrogens, comparison of, 843
 - protective effect against breast cancer, in *BRCA* gene mutation carriers, 450
 - risks of, 464
 - stroke risk with, 464
 - thromboembolic disease risk with, 464
 - and thrombosis risk in antiphospholipid syndrome, 36
 - tibolone as, 372
 - types of, 464
 - and uterine leiomyomas, 316, 364, 372
- Horse chestnut
- in cardiovascular health, 814
- extract (HCSE), 814
- adverse effects and side effects of, 814
- Hospice care, in neonatal intensive care unit, 750
- Hot flashes, menopausal, hormone replacement therapy and, 464
- Human chorionic gonadotropin (HCG)
- in diagnosis of hydatidiform mole, 485
 - and morning sickness, 653
- Human Genome Project, 425
- Human immunodeficiency virus 1 (HIV-1)/infection
- AIDS-free survival in, pregnancy and, 154
 - asymptomatic, 137
 - biology of, in women and men, 137
 - in breast milk, 198
 - CD4+ cell count in, 137
 - in children, 243
 - correlation of complications with, 167
 - measurement of, 167
 - pregnancy and, 154
 - and risk of vertical transmission, 198
 - in children. *See* Pediatric AIDS
 - clinical course of
 - contraceptive method and, 226
 - sexually transmitted diseases and, 226
 - course of, 137, 154
 - culture of, 243
 - diagnosis of, 167
 - effects on women's sexual behaviors, 289
 - end-of-life issues in, 300
 - epidemiology of, 167, 198
 - among women in United States, 154
 - international trends in, 154
 - ethical issues related to, 300
 - in female genital tract, 144
 - immunology of, 144
 - mediators of, 144
 - and fertility, 154
 - fetal
 - mechanisms of, 198, 243
 - timing of, 198, 243
 - tissue distribution of, 198
 - genetic heterogeneity of, 137
 - genetic resistance to, 137
 - genetic structure of, 137
 - in genital mucosa, source of, 144
 - geographic distribution of, 154, 167
 - immunopathogenesis of, 137
 - laboratory evaluation for, 167
 - legal issues related to, 300
 - life cycle of, 137
 - of lower female genital tract, mechanism of, 144
 - and mandatory contact/partner notification, 300
 - mother-to-child transmission of. *See* Human immunodeficiency virus 1 (HIV-1), vertical transmission of
 - newly diagnosed in pregnancy, management of, 182, 243
 - obstetric considerations in, 154
 - occupational exposure to, 276
 - baseline evaluation of exposed health care worker in, 276
 - epidemiology of, 276
 - history-taking for, 276
 - infection risk with, assessment of, 276
 - interventions for, 276
 - management of, 276
 - monitoring of exposed health care worker in, 276
 - by occupation, 276
 - postexposure prophylaxis for, 276
 - adverse effects and side effects of, 276
 - drug interactions with, 276
 - failure of, 276
 - regimens for, 276
 - registries, 276
 - resources for, 276
 - in pregnancy, management of, 276
 - risk factors for HIV infection after, 276
 - seroconversion after, incidence of, 276
 - sources of virus in, 276
 - transmission rates with, 276
 - types of, 276
- p24 antigenemia
- detection of, 243
 - and risk of vertical transmission, 198
- and patient confidentiality, 300
- pediatric. *See* Pediatric AIDS
- perinatal transmission of
- antiretroviral therapy and, 154, 243
 - genetic resistance to, 137
 - prevention of, 154, 243
 - risk factors for, 154
- polymerase gene, 137
- populations at risk for, 167
- in pregnancy, 135
- and maternal-fetal conflicts, 300
 - maternal therapy for, 182, 243
 - standards of care for, 210

- pregnancy and, 135, 154
 - case study of, 300
 - studies of, advances in (future directions for), 154
- and pregnancy-related complications, 154
- progression of, 137
 - effect of pregnancy on, 154, 198
 - predictors of, 167
 - sexually transmitted disease and, 226
- quasispecies of, 137
- replication
 - dynamics of, 137
 - hormonal factors affecting, 144
 - menstrual cycle and, 144
- reproductive behavior of women with, 289
- and reproductive decision-making, 154
- risk factors for, 167
 - behavioral interventions directed at, 289
- RNA
 - maternal levels of, and perinatal transmission of HIV, 154, 182, 243
 - and pathogenesis, 137
 - in plasma *versus* cervicovaginal lavage fluid, 137
 - in women *versus* men, 137, 154
- screening for, 300
 - in semen donors, 276
- serostatus
 - and condom use by infected women, 289
 - disclosure to partner, by infected women, 289
 - and risk of sexually transmitted disease, 289
- sexual behavior of women with, 289
- sexual transmission of, 154
 - biologic host factors affecting, 226
 - genetic resistance to, 137
 - HIV-2 preexposure and, 144
 - prevention of, 289
 - microbicidal agents for, 226
 - protective immunity to, correlates of, 144
- shedding, in female genital tract
 - correlates of, 144
 - hormonal factors affecting, 144
 - menstrual cycle and, 144
- in sperm, 198
- testing for
 - in children, 243
 - ethical considerations in, 300
 - in newborns, ethical considerations in, 300
 - in pregnant women, ethical considerations in, 300
- tissue reservoirs of, 137
- transmission of
 - by direct contact with nonintact skin of health care worker, 276
 - by mucous membrane exposure of health care worker, 276
 - by percutaneous exposure of health care worker, 276
- treatment of, in pregnancy, 182
- use of water in labor and birth and, 733
- vertical transmission of, 135
 - antepartum, 198, 243
 - in breastfeeding, 198
 - determinants of, 198, 243
 - epidemiology of, 198, 243
 - geographic variations in, 198
 - intrapartum, 198, 243
 - maternal factors affecting, 198, 243
 - mechanisms of, 198
 - obstetric factors affecting, 198, 243
 - peripartum, 198, 243
 - placental factors affecting, 198
 - postpartum, 198, 243
 - prevention of, 210, 243
 - intrapartum interventions for, 210, 243
 - obstetric interventions for, 198, 210, 243
 - pharmacologic interventions for, 210, 243
 - postnatal interventions for, 210, 243
 - short-course therapies for, 210, 243
 - standards of care for, 210
 - research on, advances in (future directions for), 210
 - risk factors for, 198
 - timing of, 198, 243
 - virologic factors affecting, 198, 243
- viral load
 - assay for, 167
 - and pathogenesis, 137
 - as predictor of disease progression, 167
 - reduction of, and prevention of vertical transmission, 210
 - and risk of vertical transmission, 198, 210, 243
 - systemic and genital, correlation between, 144
- in women
 - age distribution of, 154, 198, 243
 - and cervical cancer, 167
 - clinical presentation of, 167
 - course of, 137
 - epidemiology of, 167, 198, 243
 - gynecologic care in, 226
 - gynecologic manifestations of, 167
 - and hormonal function, 167
 - and human papillomavirus infection, 167
 - and idiopathic genital ulcers, 167
 - and menstrual function, 167
 - opportunistic infections in, 167
 - prevention of, in pregnancy, 182
 - pathogenesis of, 137
 - postpartum considerations in, 182
 - prevalence of, 144, 154, 198
 - prognosis for, 167
 - progression of, predictors of, 167
 - racial distribution of, 154, 167, 243
 - risk factors for, 154
 - and sexually transmitted disease, 167
 - standards of care for, 210
 - survival rate for, 167
 - treatment of, 167. *See also* Antiretroviral therapy during pregnancy, 182
 - trends in, 154
 - X4 strains, 137
- Human immunodeficiency virus 2 (HIV-2)
 - biology of, 137
 - preexposure to, protective effect against HIV-1, 144
 - use of water in labor and birth and, 733
- Human papillomavirus (HPV)
 - infection
 - and cervical dysplasia, 538
 - in HIV-infected (AIDS) patients, 167, 226
 - reflex testing for, 538
 - testing, in cervical cancer screening, 538
- Hydatidiform mole, diagnosis of
 - human chorionic gonadotropin in, 485
 - ultrasound in, 485
- Hydrotherapy, for labor analgesia, 704

- Hydroxyurea
 teratogenicity of, 182
 use in pregnancy, preclinical and clinical data relevant to, 182
- Hypercoagulable state, generation of, antiphospholipid antibodies and, 11
- Hyperemesis gravidarum. *See also* Morning sickness
 epidemiology of, 653
 pathophysiology of, 653
 treatment of, 653
- Hypericin, 824
- Hypericum perforatum*. *See* St. John's wort
- Hyperlipidemia
 garlic for, 814
 and thrombosis risk in antiphospholipid syndrome, 36
- Hypertension
 garlic for, 814
 and hemorrhagic stroke risk, 62
 and ischemic stroke, 62
 and myocardial infarction risk, 62
 and thrombosis risk in antiphospholipid syndrome, 36
 and uterine leiomyomas, 316
- Hyperthyroidism, and morning sickness, 653
- Hypnosis
 definition of, 681
 in labor and delivery, 681, 704
- Hypoandrogenism, in women, 880
- Hypophysis L., 853
- Hypotension, garlic and, 814
- Hysterectomy
 abdominal, for myomatous uterus, 385
 annual rate of, 385
 in *BRCA* gene mutation carriers, 450
 complications of, 385
 for myomatous uterus, 335, 385, 425
 complications of, 412
 GnRH analog pretreatment with, 385
 indications for, 385
 laparoscopically assisted, 385
 numbers of, 412, 425
- peripartum, 571
- radical, with lymph node dissection, for cervical cancer, 531
- traditional Chinese medicine and, 801
- vaginal, for myomatous uterus, 385
- Hysterosalpingography, of uterine leiomyomas, 385
- Hysteroscopy, of myomatous uterus, 385
- I**
- Immune system, 144
 adaptive, 144
 dehydroepiandrosterone and, 880
 of female genital tract
 HIV-mediated dysregulation of, 144
 and protection against HIV, 144
 growth hormone and, 893
 humoral, 144
 innate, 144
- Immunization(s)
 for HIV-infected (AIDS) patients, in pregnancy, 182
 for pediatric AIDS patients, 243
- Immunoglobulin, intravenous (IVIG)
 for antiphospholipid antibody-related infertility, 29
 for antiphospholipid syndrome during pregnancy, 20
 for classic (definite) antiphospholipid syndrome, in pregnancy, 20
- Immunohistochemistry, of uterine tumors, 350
- Immunologic therapy
 for antiphospholipid antibody-related infertility, 29
 for antiphospholipid syndrome during pregnancy, 20
- Immunotherapy, genetic, 425
- Implanon, 92
- Implantation, uterine leiomyomas and, 364, 385
- Incontinence, urinary, uterine leiomyomas and, 364, 385
- Indian Health Service, 661
- Indinavir, 243
 use in pregnancy, preclinical and clinical data relevant to, 182
- Infant(s), HIV-positive, treatment of, 243
- Infant massage, 750
- Infant mortality rate, 571
 in United States, 553, 671
- Infection(s)
 after uterine artery embolization for myomas, 412
 opportunistic
 in HIV-infected (AIDS) patients, prevention of, 167
 in pregnancy, 182
 in pediatric AIDS, 243
 prophylaxis for, 243
 in pediatric AIDS, 243
 pulmonary, in pediatric AIDS, 243
 skin, in pediatric AIDS, 243
 use of water in labor and birth and, 733
 of uterine leiomyomas, 385
- Infection control, 276
- Inferior vena caval thrombosis, in antiphospholipid syndrome, 36
- Infertility
 antiphospholipid antibody-related, 29
 and clinical practice, 29
 treatment of, 29
 uterine leiomyomas and, 316, 364, 385, 401
- Informed consent
 for elective repeat cesarean, 622
 for genetic testing, 450
 for vaginal birth after cesarean delivery, 622
- Insomnia, valerian for, 824
- Institute for Nutraceutical Advancement (INA), Methods Validation Program for botanicals, 789
- Insulin-like growth factor, and growth hormone, 893
- Insulin-like growth factor(s), in uterine leiomyomas, 327
- Integrative medicine, 640
- Interferon(s)
 antiangiogenic effects of, 327
 for uterine leiomyomas, 327, 372
- Intermittent claudication, ginkgo biloba for, 814
- Internal organs
 menstruation and, in traditional Chinese medicine, 801
 in traditional Chinese medicine, 801
- Internet resources
 on complementary and alternative medicine, 902
 on growth hormone secretagogues, 893
- Intestinal angina, in antiphospholipid syndrome, 36
- Intestinal infarction, in antiphospholipid syndrome, 36
- Intrauterine device (IUD)
 for postcoital contraception, 101
 and uterine leiomyomas, 316

- Intrauterine growth retardation (IUGR), in antiphospholipid syndrome, 2
- Intravenous drug abuse, and HIV infection, 167
- Intravenous excretory urography, in gynecologic oncology, 485
- In vitro fertilization-embryo transfer (IVF-ET), antiphospholipid antibodies and, 29
- In vitro fertilization (IVF), pregnancy rates with, uterine leiomyomas and, 364, 385
- Ipriflavone
 - adverse effects of, 836
 - and bone mineral density, 836
- Isoflavones
 - adverse effects of, 836
 - and bone mineral density, 836, 843
 - in breast cancer prevention, 836, 843
 - cardioprotective effects of, 843
 - and cholesterol levels, 836
 - as phytoestrogens, 836
 - red clover-based, for menopausal symptoms, 853
- J
- Jarsin. *See* St. John's wort
- K
- Kangaroo care, and neonatal healing, 750
- Kaposi's sarcoma, in HIV-infected (AIDS) patients, 167
 - clinical presentation of, in women, 167
- Kavain, 824
- Kava kava
 - Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 - central nervous system effects of, 824
 - drug interactions with, 824
 - extract (WS 1490), 824
 - adverse effects and side effects of, 824
 - Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
- Kaveri, 814, 824
- Kawain, 824
- Keloids
 - insulin-like growth factor expression in, 327
 - pathology of, 327
- 3-Keto-desogestrel
 - combinations, vaginal ring delivery system for, 106
 - vaginal ring delivery system for, 106
- Kidney(s)
 - in pediatric AIDS, 243
 - in traditional Chinese medicine, 801
- Korean ginseng. *See* Ginseng, Chinese
- Kwai, 814
- L
- Labor. *See also* Home birth
 - acupuncture in, 681, 704
 - analgesia for
 - acupressure in, 704
 - acupuncture for, 704
 - biofeedback and, 681, 704
 - electroacupuncture in, 704
 - herbal medicine in, 704
 - hydrotherapy in, 704
 - hypnosis and, 681, 704
 - mechanism of action of, 704
 - mind/body interventions and, 681
 - music therapy in, 704
 - transcutaneous electrical nerve stimulation (TENS) and, 681
 - transcutaneous electrical nerve stimulation (TENS) for, 704
 - use of complementary and alternative medicine in, 681
 - use of water in labor and birth and, 733
 - augmentation of
 - after previous cesarean delivery, 561, 588
 - herbal medicine in, 681
 - homeopathy in, 681
 - and risk of uterine rupture during trial of labor, 609
 - transcutaneous electrical nerve stimulation (TENS) and, 681
 - use of complementary and alternative medicine in, 681
 - black cohosh and, 681
 - blue cohosh and, 681
 - duration of
 - hypnosis and, 681
 - mind/body interventions and, 681
 - dysfunctional, and risk of uterine rupture during trial of labor, 609
 - induction of
 - acupuncture in, 681
 - after previous cesarean delivery, 561, 588
 - electroacupuncture in, 681
 - and risk of uterine rupture during trial of labor, 609
 - transcutaneous electrical nerve stimulation (TENS) and, 681
 - use of complementary and alternative medicine in, 681
 - management of, after previous cesarean delivery, 588
 - Native Americans and, 661
 - pain relief in. *See* Labor, analgesia; Pain relief, in labor and delivery
 - prolonged, uterine leiomyomas and, 364
 - trial of
 - after previous cesarean delivery, 561, 604
 - candidates for, 588
 - versus* elective cesarean, 594, 604
 - literature review on, 609
 - management of, 588, 594
 - risks of, reducing, 594
 - safety of. *See* Uterine rupture
 - women's views on, 594
 - use of complementary and alternative medicine in, 681
 - in water, 733. *See also* Hydrotherapy- Labor support, continuous. *See also* Doula(s)
 - benefits of, 692
 - effects on obstetric outcomes, 692
 - research on
 - from Botswana, 692
 - from Guatemala, 692
 - from Houston, 692
- Laitan, 824
- Lamivudine
 - mitochondrial toxicity of, 243
 - for pediatric AIDS, 243
 - in prevention of vertical transmission of HIV, 210
 - use in pregnancy
 - long-term effects of, 182
 - preclinical and clinical data relevant to, 182

- Laparoscopy
 adnexal mass removal by, technical feasibility of, 495
 in gynecologic cancers
 port site metastases with, 495
 prevention of, 495
 and rate of metastases, 495
 survival rate for, *versus* traditional management, 495
 and timing of surgical staging, 495
 lymphadenectomy using, 495
 in management of adnexal mass, 495
 for myomectomy, 401
 in staging of gynecologic cancers, 495
 with uterine leiomyomas, 401
 in vaginal hysterectomy, for myomatous uterus, 385
 Lavender oil, for perineal discomfort, 704
 Legal considerations
 in alternative therapies for pain in labor, 704
 in care of HIV-infected (AIDS) patients, 300
 with vaginal birth after cesarean delivery, 571, 622
 Leiomyoblastoma, pathology of, 350
 Leiomyomas
 in pediatric AIDS, 243
 uterine. *See also* Leiomyomata uteri
 depot medroxyprogesterone acetate for, 73
 reduced risk of, oral contraceptives and, 62
 Leiomyomata uteri
 abnormal vaginal bleeding with, 364
 age at menarche and, 316
 animal models of, 335, 425
 apoplectic, 350
 asymptomatic, 335, 364, 385
 management of, 372, 385
 atypical, 350
 with low risk of recurrence, 350
 atypical gross features of, 350
 bcl-2 protein in, 327
 benign metastasizing, 350
 biology of, *in vitro* studies of, 327
 biopsy of, indications for, 412
 bizarre, 350
 cellular, 350
 hemorrhagic, 350
 childbearing history and, 316
 clonality of, 335
 cytogenetic abnormalities with, 335, 385
 as secondary changes, 335
 degeneration of, during pregnancy, 364
 diagnosis of, 401
 rates of, *versus* true occurrence rates, 316
 differential diagnosis of, 350, 385
 distribution of, 350, 364
 epidemiologic studies of
 advances in (future directions for), 316
 methodologic challenges in, 316
 published, characteristics of, 316
 epidemiology of, 316
 as fibrotic disease, 327
 gene therapy for, 425
 advances in (future directions for), 425
 cytotoxic, 425
 genetics of, 335
 genetic studies of, advances in (future directions for), 316, 335
 gross morphology of, 350
 growth factors in, 327
 angiogenic, 327, 372
 growth of
 factors affecting, 385
 hormonal dependence of, 372
 with postmenopausal hormone replacement therapy, 364
 in pregnancy, 364, 385
 rate of, 364
 heritability of
 epidemiologic evidence for, 335
 genome-wide screen for, 335
 hormonal factors affecting, 316, 327, 350, 364, 372
 incidence of
 age-related, 385
 at autopsy, 372, 385
 in hysterectomy specimens, 364
 infection involving, 385
 and infertility, 316, 364, 385, 401
 insulin-like growth factor expression in, 327
 intramural, 350
 bleeding with, 364, 385
 intravascular, 350
 endometrial stromal, 350
 smooth muscle, 350
 laparoscopic approaches to, 401
 leuprolide acetate therapy and, 350
 with limited experience, 350
 of low malignant potential, with limited experience, 350
 management of, 314, 327, 425
 alternatives for, 412
 medical, 372
 preoperative, 385
 nonsurgical, 327, 364
 outcomes for, 385
 preoperative, 385
 options for, 372
 surgical, 385, 412. *See also* Hysterectomy; Myomectomy
 optional approaches for, 385
 outcomes for, 385
 preoperative counseling about, 385
 preoperative evaluation of, 385
 risks of, 385
 uterine artery embolization for, 412
 menopause and, 364
 menstrual history and, 316
 microscopic evaluation of, indications for, 350
 microscopic features of, 350
 variants of, 350
 morcellation of, 401
 mosaicism in, 335
 myxoid, 350
 number of, 364
 obstetric complications with, 364, 385
 parasitic, 350
 particles, in abdominal wall incision for laparoscopic myomectomy, 401
 pathogenesis of, 327, 350
 pathology of, 350
 pedunculated, 350
 differential diagnosis of, 350
 infarction of, 385

- management of, 412
- torsion of, 364, 385
- pelvic pain caused by, 364
- pleomorphic, 350
- prevalence of, 316, 327, 335, 350, 364, 372, 385, 412
 - age-related, 316, 335
 - at autopsy, 412
 - race and, 316, 372
- recurrence of
 - after laparoscopic myomectomy, 401
 - after myomectomy, 385, 425
- removal of. *See also* Hysterectomy; Myomectomy
 - quality of life after, 385
 - symptoms necessitating, 385
- reproductive dysfunction caused by, 364, 385
- risk factors for, 316
 - public health implications of, 316
- sarcomatous change in, 335, 364
 - incidence of, 385
- signs and symptoms of, 335, 364, 385, 412
 - changes in, over time, 364
- size of, 364, 372, 385
 - and hysterectomy, 385
 - pregnancy and, 364
- submucosal, 350
 - bleeding with, 364, 385
 - management of, 412
- subserosal, 350
 - bleeding with, 385
 - management of, 412
- symplastic, 350
- unusual behavior of, 350
- urinary symptoms caused by, 364
- with vascular invasion, 350
- vascular supply of, 350, 372
- Leiomyomatosis, diffuse, 350
- Leiomyomatosis disseminata peritonealis, pathology of, 350
- Leiomyosarcoma(s)
 - gross morphology of, 350
 - incidence of, in hysterectomy specimens, 364, 385
 - microscopic features of, 350
 - myxoid, 350
 - pathogenesis of, 364
 - pathology of, 350
 - in pediatric AIDS, 243
 - prevalence of, 350
- Leishmaniasis, antiphospholipid antibodies in, 48
- Lepirudin, 36
- Leptospirosis, antiphospholipid antibodies in, 48
- Leuprolide acetate therapy. *See also* Gonadotropin-releasing hormone (GnRH) analogs
 - and leiomyomas, 350
 - for uterine leiomyomas, preoperative, 401
- Levonorgestrel
 - mechanism of action of, 92
 - vaginal ring delivery system for, 106
- Levonorgestrel/norgestrel combination, vaginal ring delivery system for, 106
- L-692,429 (growth hormone secretagogue), 893
- LI 160, 824
- LI 1370, 824
- Libido, reduced, with injectable long-acting contraceptives, 73
- Licensure, of health professionals, 640
- Licorice
 - for Addison disease, 853
 - for menopausal symptoms, 853
- LI 132 (Faros), 814
- Lifestyle, changes, and breast cancer prevention, 478
- Li-Fraumeni syndrome, genetics of, 450
- Light therapy, in neonatal intensive care unit, 750
- Lignans, as phytoestrogens, 836
- γ -Linolenic acid, evening primrose and, 853
- Lipids, plasma, injectable long-acting contraceptives and, 73
- Lipoleiomyoma, pathology of, 350
- Liquorice. *See* Licorice
- Liver, in traditional Chinese medicine, 801
- LI 160 WS, 824
- Lopinavir/ritonavir, for pediatric AIDS, 243
- Low birthweight
 - in infants of HIV-infected mothers, 154, 182
 - leiomyomas and, 364
- Lunelle
 - adverse effects and side effects of, 73
 - comparison with other contraceptive methods, 73
 - concomitant medication use and, 73
 - continuation of, physician's role in, 73
 - contraceptive efficacy of, 73
 - contraindications to, 73
 - decreased libido with, 73
 - discontinuation of, return to fertility after, 73
 - dosage and administration of, 73
 - FDA approval of, 73
 - formulation of, 73
 - inadvertent administration during pregnancy, 73
 - initial and subsequent injections, timing of, 73
 - mechanism of action of, 73
 - menstrual changes with, 73
 - pharmacokinetics of, 73
 - pharmacology of, 73
 - and plasma lipid levels, 73
 - procoagulant effects of, 73
 - and reduced cardiovascular disease risk, 73
 - and reproductive tract cancer risk, 73
 - weight changes with, 73
- Lung(s), in traditional Chinese medicine, 801
- Lung disease, in pediatric AIDS, 243
- Lupron, preoperative use of, with myomectomy, 385
- Lupus anticoagulant
 - antiphospholipid syndrome caused by, 36
 - laboratory assessment for, 36, 48
 - management of, during pregnancy, 20
 - and pregnancy loss, 11
 - and risk of pregnancy loss, 2
- Lymphadenectomy, laparoscopic, 495
- Lymphadenopathy, as presenting HIV-related condition, 167
- Lymphangiograms, in gynecologic oncology, 485
- Lymphocyte(s), in HIV-infected (AIDS) patients, pregnancy and, 154
- Lymphography, scintigraphic, in gynecologic oncology, 485
- Lymphoid interstitial pneumonitis, in pediatric AIDS, 243
- Lymphoma
 - endometrial, in HIV-infected (AIDS) patients, 167
 - in pediatric AIDS, 243

- M**
- Macrosomia**
and risk of uterine rupture during trial of labor, 609
suspected, and vaginal birth after cesarean delivery, 588
- Mad cow disease.** *See* Bovine spongiform encephalopathy
- Magnetic resonance imaging (MRI)**
of adenomyosis, 385, 412
in gynecologic oncology, 485
of uterine leiomyomas, 385, 412
evaluation of response to GnRH-analog therapy, 385
- Malignancy, in pediatric AIDS, 243**
- Malpractice liability, 571, 622**
alternative medicine and, 640
- Manual healing, 640.** *See also* Touch, therapeutic
in labor and delivery, 704
- Massage**
in aromatherapy, 704
lower back, in labor, 704
perineal, 704
therapeutic, in labor and delivery, 704
- Massage therapy, and neonatal healing, 750**
- Mastalgia, evening primrose for, 853**
- Mastectomy, prophylactic, in *BRCA* gene mutation carriers, 478**
- Mastodynia**
evening primrose for, 853
vitex for, 853
- Maternal age**
and cesarean delivery, 553
and risk of uterine rupture during trial of labor, 609
- Maternal-fetal conflicts, HIV-infected (AIDS) patients and, 300**
- Maternal mortality rate**
in childbirth, 553, 671
peripartum, 571
- Meditation, in traditional Chinese medicine, 801**
- Medroxyprogesterone acetate, depot (DMPA)**
adverse effects and side effects of, 73
and coagulation, 73
comparison with other contraceptive methods, 73
concomitant medication use and, 73
continuation of, physician's role in, 73
contraindications to, 73
decreased libido with, 73
discontinuation of, return to fertility after, 73
dosage and administration of, 73
FDA approval of, 73
formulation of, 73
HIV-infected women and, 226
inadvertent administration during pregnancy, 73
indications for, 73
injections, initial and subsequent, timing of, 73
mechanism of action of, 73
menstrual changes with, 73
mood changes with, 73
noncontraceptive benefits of, 73
pharmacokinetics of, 73
and plasma lipid levels, 73
and reduced cardiovascular disease risk, 73
and risk of uterine leiomyomas, 316
therapeutic uses of, 73
weight changes with, 73
- Megestrol, vaginal ring delivery system for, 106**
- Memory, ginkgo and, 824**
- Men, as childbirth companions, 692**
- Menometrorrhagia, with uterine leiomyomas, 364, 385**
- Menopausal symptoms**
anabolic steroids for, 880
androgens for, 880
botanical medicine for, 853
estriol for, 864
vaginal ring hormone delivery system for, 106
- Menopause**
traditional Chinese medicine and, 801
and uterine leiomyomas, 316, 364
- Menorrhagia**
depot medroxyprogesterone acetate for, 73
of hypermenorrhea, 372
with uterine leiomyomas, 364, 372
- Menstrual bleeding, abnormal, with uterine leiomyomas, 364, 385**
- Menstrual changes**
with implantable contraceptives, 92
with injectable long-acting contraceptives, 73
vitex for, 853
- Menstrual cycle**
in HIV-infected (AIDS) patients, 167
and HIV replication, 144
- Menstrual disorders**
in HIV-infected (AIDS) patients, 167, 226
relief from, oral contraceptives and, 62
- Menstruation**
and internal organs, in traditional Chinese medicine, 801
physiology of, traditional Chinese medicine and, 801
- Methysticin, 824**
- Metrorrhagia, with uterine leiomyomas, 364**
- Microbicidal agent(s)**
contraceptive, for HIV-infected women, 226
in prevention of HIV transmission, 226
- Microsatellite instability, 450**
- Midwifery**
historical perspective on, 671
and home birth, 671
- Mifepristone**
adverse effects and side effects of, 372
for labor induction, after previous cesarean delivery, 588
for postcoital contraception, 101
for uterine leiomyomas, 372
- Migraine, and ischemic stroke, 62**
- Milk thistle**
Association of Official Agricultural Chemists' task force on dietary supplements and, 789
Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
- Mind/body interventions, 640**
efficacy of, clinical trial evidence of, 902
integration into clinical practice, 902
in labor and delivery, 681, 704
in traditional Chinese medicine, 801
- Misoprostol, for labor induction**
after previous cesarean delivery, 588, 622
and risk of uterine rupture during trial of labor, 609
- Mitochondria, antiretroviral therapy and, 182, 210, 243**
- MK-677 (growth hormone secretagogue), 893**
- MLH1* gene, mutations**

- and breast cancer, 450
 - and endometrial cancer, 450
 - and hereditary nonpolyposis colorectal cancer, 450
 - Mood changes, with injectable long-acting contraceptives, 73
 - Morcellator(s), for uterine leiomyomas, 401
 - Morning sickness. *See also* Hyperemesis gravidarum
 - acupressure for, 653
 - alternative therapies for, 653
 - literature on, 653
 - causes of, 653
 - complications of, 653
 - evolutionary purpose of, 653
 - ginger for, 653
 - incidence of, 653
 - protective role of, 653
 - as psychogenic disorder, 653
 - pyridoxine for, 653
 - treatment of, 653
 - Bendectin in, 653
 - rationale for, 653
 - Mosaicism, in uterine leiomyomas, 335
 - Moxibustion, 681, 704
 - MPA/E₂C. *See* Lunelle
 - MSH2* gene, mutations
 - and endometrial cancer, 450
 - and hereditary nonpolyposis colorectal cancer, 450
 - and ovarian cancer, 450
 - MSH6* gene, mutations, and hereditary nonpolyposis colorectal cancer, 450
 - Mullerian tumor, malignant mixed, 350
 - Multifetal pregnancy
 - and risk of uterine rupture during trial of labor, 609
 - and vaginal birth after cesarean delivery, 561, 588
 - Multi-infarct dementia, ginkgo for, 824
 - Muscle tension release
 - in labor and delivery, 704
 - technique for, 704
 - Music therapy
 - bedside, 704
 - during childbirth, 681
 - in labor and delivery, 704
 - in neonatal intensive care unit, 750
 - Mycobacterium avium* complex infection
 - in HIV-infected (AIDS) patients, management of, in pregnancy, 182
 - in pediatric AIDS, 243
 - prophylaxis for, 243
 - Myocardial infarction, oral contraceptives and, 62
 - Myofibromas, uterine. *See* Leiomyomata uteri
 - Myolysis, laparoscopic, 401
 - Myoma(s). *See* Leiomyomata uteri
 - Myomectomy, 385
 - blood loss during, limiting, 385
 - complications of, 385
 - conversion to hysterectomy, 385
 - drawbacks of, 412
 - fertility after, 385, 425
 - fever after, 385
 - GnRH analog pretreatment with, 385
 - laparoscopic, 401
 - adenomyosis after, 401
 - complications of, 401
 - fertility after, 401
 - intraoperative considerations in, 401
 - myometrial repair in, 401
 - and parasitic leiomyoma particles in abdominal wall incision, 401
 - preoperative evaluation for, 401
 - preoperative therapy with, 401
 - removal of myoma from abdomen in, 401
 - technique for, 401
 - uterine rupture after, 401
 - laparoscopy-assisted, 401
 - uterine rupture after, 401
 - numbers of, 425
 - pregnancy complications after, 385
 - preoperative counseling about, 385
 - preoperative medical treatment with, 385
 - drawbacks of, 385
 - risks of, 385
 - surgical technique for, 385
 - Myometrium
 - benign hypertrophy of, pathology of, 350
 - insulin-like growth factor expression in, 327
 - repair of, in laparoscopic myomectomy, 401
- N
- Nadrolone decanoate, 880
 - Nadroparin, for thrombosis in antiphospholipid syndrome, 36
 - Naphthalene sulfonate, in prevention of HIV transmission, 226
 - National Center for Complementary and Alternative Medicine, 774, 801
 - and acupuncture, 801
 - contact information for, 640
 - functions of, 640
 - National Institutes of Health (NIH)
 - Office of Alternative Medicine. *See* National Center for Complementary and Alternative Medicine
 - report on cesarean delivery, 561
 - National Nutritional Foods Association and Good Manufacturing Practices for dietary supplements, 789
 - TruLabel program, 789
 - Native Americans
 - antepartum care among, 661
 - core cultural concepts of, 661
 - culture of, 661
 - herbal medicine used by, 661
 - history-taking with, 661
 - intrapartum care among, 661
 - medicine
 - comparison with modern Western medicine, 661
 - core concepts of, 661
 - perception of time among, 661
 - persona of, 661
 - postpartum care among, 661
 - rituals and ceremonies of, 661
 - spirituality of, 661
 - traditional practices of, in obstetrics, 661
 - Nausea
 - with oral contraceptives, 62
 - pregnancy-associated. *See* Morning sickness

- Needlestick(s)
 frequency of, 276
 management of, 276
 patient's HIV status and, 300
- Neisseria gonorrhoeae* cervicitis, in HIV-infected (AIDS) patients, 167
- Nelfinavir
 for pediatric AIDS, 243
 use in pregnancy, preclinical and clinical data relevant to, 182
- Neonatal injury, with obstetric trauma, 571
- Neonatal intensive care unit
 acupuncture in, 750
 aromatherapy in, 750
 bioenergetic therapy in, 750
 biomechanical therapy in, 750
 chiropractic therapy in, 750
 complementary care in, 750
 nursing care and, 750
 rationale for, 750
 energy workers in, 750
 herbal medicine in, 750
 homeopathy in, 750
 hospice care in, 750
 kangaroo care in, 750
 length of stay in, 571
 light and color therapy in, 750
 massage therapy in, 750
 osteopathy in, 750
 reflexology in, 750
 reiki in, 750
 sound and music therapy in, 750
 therapeutic touch in, 750
- Neoplasia
 lower genital tract, in HIV-infected (AIDS) patients, 226
 in pediatric AIDS, 243
- Nestorone
 combinations, vaginal ring delivery system for, 106
 vaginal ring delivery system for, 106
- Neutropenia, in pediatric AIDS, 243
- Nevirapine
 for pediatric AIDS, 243
 in prevention of vertical transmission of HIV, 210, 243
 use in pregnancy, preclinical and clinical data relevant to, 182
- Newborn
 antiretroviral therapy for, 210, 243
 HIV-positive, treatment of, 243
 of HIV-positive mother, treatment of, 243
 HIV testing in, 300
- Nonoxonyl-9, 226
- 19-Norandrostenedione, 880
- 19-Nor complex, 880
- Norethindrone combinations, vaginal ring delivery system for, 106
- Norgestimate, in oral contraceptives, 62
- Norgestrel. *See also* Levonorgestrel/norgestrel combination
 vaginal ring delivery system for, 106
- Norgestrienone, vaginal ring delivery system for, 106
- Norplant
 adolescents' use of, 114
 advantages and disadvantages of, 92
 adverse effects and side effects of, 92
 candidates for, 92
 continuation rates with, 92
 contraindications to, 92
 controversy about, 92
 efficacy of, 92
 historical perspective on, 92
 implant system for, 92
 insertion of, 92
 mechanism of action of, 92
 public health concerns with, 92
 removal of, 92
- Norplant II, 92
- Norvir. *See* Ritonavir
- Nutrition Education and Labeling Act (1990), 780
- O
- Obesity, and uterine leiomyomas, 316
- Oligomenorrhea, in HIV-infected (AIDS) patients, 226
- Oophorectomy, prophylactic, in *BRCA* gene mutation carriers, 478
 occult cancer discovered at, 450
 protective effect against cancer, 450
- Operative injury, obstetric, 571
- Opportunistic infection(s)
 AIDS-defining, 167
 in HIV-infected (AIDS) patients, prevention of, 167
 in pregnancy, 182
 in pediatric AIDS, 243
 prophylaxis for, 243
- Oral contraceptives
 adolescents' use of, 114
 and breast cancer risk, 62
 cardiovascular risks with, 62
 combination pills, for postcoital contraception, 101
 comparison with other contraceptive methods, 73
 compliance with, side effects and, 62
 contraindications to, in classic (definite) antiphospholipid syndrome, 20
 current status of, 62
 effectiveness of, 62
 HIV-infected women and, 226
 mechanism of action of, 62
 new developments in, 62
 noncontraceptive health benefits of, 62
 for postcoital contraception, 101
 procoagulant effects of, 73
 progestin-only, for postcoital contraception, 101
 protective effect against ovarian cancer, in *BRCA* gene mutation carriers, 450
 reduced estrogen dose in, 62
 side effects of, 62
 and thrombosis risk in antiphospholipid syndrome, 36
 traditional Chinese medicine and, 801
 use-effectiveness of, 62
 and uterine leiomyomas, 316
- Osteopathy, and neonatal healing, 750
- Osteoporosis
 heparin-induced, 36
 phytoestrogens and, 836, 843
 prevention
 estriol for, 864
 hormone replacement therapy and, 464, 864
 raloxifene for, 478
- Ovarian cancer. *See also* Hereditary breast and ovarian cancer

- chemotherapy for, 522
 - diagnosis of, 522
 - CA-125 measurement in, 495, 522
 - laparoscopy in, 495
 - differential diagnosis of, 522
 - epidemiology of, 522
 - follow-up for, 485
 - in hereditary nonpolyposis colorectal cancer syndrome, 450
 - intraoperative rupture of, clinical significance of, 495
 - laboratory findings in, 522
 - laparoscopic procedures for, and port site metastases, 495
 - metastases, 485
 - laparoscopy and, 495
 - radiographic imaging in, 485
 - recurrent
 - chemotherapy for, 522
 - disease-free interval in, 522
 - management of, 522
 - platinum-free interval in, 522
 - residual disease after chemotherapy for, 485
 - risk
 - hormone replacement therapy and, 464
 - injectable long-acting contraceptives and, 73
 - reduced, oral contraceptives and, 62
 - risk factors for, 522
 - screening for, 450, 522
 - single nucleotide polymorphisms and, 450
 - staging of, 495
 - laparoscopic, 495
 - and survival, 522
 - surgery for, 522
 - survival rates for, 522
 - survivors, hormone replacement therapy in, 464
 - treatment of
 - laparoscopic
 - and risk of metastases, 495
 - survival rates with, 495
 - options for, 522
 - second-look operation in, 522
 - traditional (laparotomy), survival rates with, 495
- Ovarian cysts
- imaging of, 485
 - malignant, intraoperative spill from, clinical significance of, 495
 - protection against, oral contraceptives and, 62
 - suppression of, injectable long-acting contraceptives and, 73
- Ovarian hemorrhage, with supratherapeutic anticoagulation, 36
- Ovulation, physiology of, and pathophysiology of ovarian cancer, 522
- Oxytocin, use of
 - after previous cesarean delivery, 561, 588, 622
 - and risk of uterine rupture during trial of labor, 609, 622
- P
- Paclitaxel, for ovarian cancer, 522
- Pain, gate control theory of, 681, 704
- Pain relief, in labor and delivery. *See also* Labor, analgesia for
- acupressure for, 704
 - acupuncture for, 681, 704
 - alternative therapies for, 704
 - biofeedback for, 704
 - doula's role in, 692
 - electroacupuncture for, 704
 - herbal medicine for, 704
 - hydrotherapy for, 704
 - hypnosis and, 681, 704
 - intracutaneous nerve stimulation for, 704
 - massage therapy and, 704
 - mind/body interventions for, 704
 - music therapy for, 704
 - reflexology and, 704
 - sterile water blocks for, 704
 - transcutaneous electrical nerve stimulation (TENS) for, 704
 - use of water in labor and birth and, 733
- Panax. *See also* Ginseng
- Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 - Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
- Pancreatic cancer, *BRCA* gene mutations and, 450
- PAPNET, 538
- Pap test
 - computer-assisted screening of, 538
 - false-negative rate of, 538
 - for HIV-infected (AIDS) patients, 226
 - interpretation of, 226
 - recommendations for, 167
 - interpretation of
 - Bethesda System for, 538
 - errors in, 538
 - liquid-based cytology and, 538
 - sensitivity of, 538
- Parents, and adolescent sexuality, 114
- Pediatric AIDS. *See also* Human immunodeficiency virus 1 (HIV-1)/infection, vertical transmission of
- antiretroviral therapy for, 243
 - agents for, 243
 - guidelines for, 243
 - cardiac involvement in, 243
 - CD4+ cell counts in, 243
 - clinical classification of, 243
 - clinical features of, 243
 - cutaneous manifestations of, 243
 - development in, 243
 - diagnosis of, 243
 - disease progression in, predictors of, 243
 - epidemiology of, 243
 - gastrointestinal involvement in, 243
 - hematologic abnormalities in, 243
 - historical perspective on, 210
 - immunizations in, 243
 - immunologic classification of, 243
 - infectious complications of, 243
 - prophylaxis for, 243
 - laboratory findings in, 243
 - medical treatment in, 243
 - neurologic abnormalities in, 243
 - nutrition in, 243
 - opportunistic infections in, 243

- prophylaxis for, 243
- organ involvement in, 243
- prevention of, 210, 243
 - intrapartum interventions for, 210, 243
 - obstetric interventions for, 198, 210, 243
 - pharmacologic interventions for, 210, 243
 - postnatal interventions for, 210, 243
 - short-course therapies for, 210, 243
 - standards of care for, 210
- prognosis for, 243
- psychosocial care in, 243
- pulmonary complications of, 243
- renal complications of, 243
- routes of HIV transmission in, 243
- and somatic growth, 243
- supportive care in, 243
- treatment of, 243
- trends in, 243
- Pediatric AIDS Clinical Trials Group protocol 076. *See* AIDS Clinical Trials Group protocol 076
- Pelvic inflammatory disease
 - in HIV-infected (AIDS) patients, 167, 226
 - protection against, oral contraceptives and, 62
 - and uterine leiomyomas, 316
- Pelvic pain, with uterine leiomyomas, 364, 385
- Pelvic pressure, with uterine leiomyomas, 364, 385
- Penrose drain tourniquet, and blood loss during myomectomy, 385
- Perfenidone, therapeutic potential of, for uterine leiomyomas, 327
- Perinatal mortality, with home birth *versus* hospital delivery, 671
- Perineal discomfort, aromatherapy for, 704
- Perineal trauma, reduction of, by use of water in labor and birth, 733
- Peripheral arterial occlusive disease, ginkgo biloba for, 814
- Peritoneal cancer, *BRC4* gene mutations and, 450
- Peutz-Jeghers syndrome, genetics of, 450
- Pharmacologic/biologic treatment, 640
- Phenetidin, in prevention of breast cancer, 478
- Physical activity, and uterine leiomyomas, 316
- Phytoestrogens
 - adverse effects of, 836
 - and bone health, 836, 843
 - in breast cancer prevention, 836, 843
 - cardioprotective effects of, 843
 - and cholesterol levels, 836
 - clinical effects of, 836
 - and cognitive function, 843
 - coumestans as, 836
 - effect on breast and endometrial cancer risk, 843
 - and ERT/HRT, comparison of, 843, 853
 - isoflavones as, 836
 - lignans as, 836
 - and menopausal vasomotor symptoms, 836
 - and osteoporosis, 836
 - pharmacologic properties of, 836
 - risks and benefits of, research on, 843
- Phytomedicine. *See* Herbal medicine
- Piper methysticum*. *See* Kava kava
- Placenta
 - as barrier to vertical transmission of HIV, 198
 - histopathology of
 - in antiphospholipid syndrome, 20
 - fetal death associated with, 11
 - mechanisms of, 11
 - in preeclampsia, 11
 - HIV infection in, 198
 - thrombosis of, antiphospholipid antibody-associated, 11, 20
- Placental anticoagulant proteins, antiphospholipid antibodies and, 11
- Placental insufficiency. *See* Uteroplacental insufficiency
- Placenta previa accreta, in patient with previous cesarean delivery, 622
- Plain film radiography, in gynecologic oncology, 485
- Platelets, antiphospholipid antibodies and, 11
- PMS1* gene, mutations, and hereditary nonpolyposis colorectal cancer, 450
- PMS2* gene, mutations, and hereditary nonpolyposis colorectal cancer, 450
- Pneumococcal disease, in pediatric AIDS, 243
- prophylaxis for, 243
- Pneumococcal vaccine, for HIV-infected (AIDS) pediatric patients, 243
- Pneumocystis carinii* pneumonia
 - in HIV-infected (AIDS) patients, management of, in pregnancy, 182
 - in pediatric AIDS, 243
 - prophylaxis for, in children, 243
- Polymorphisms, single nucleotide, and cancer risk, 450
- Polytetrafluoroethylene (Preclude), adhesion barrier, 401
- Positron emission tomography (PET), in gynecologic oncology, 485
- Postpartum care
 - doula's role in, 692
 - for HIV-infected (AIDS) patients, 182
 - for Native Americans, 661
- Prayer, and neonatal healing, 750
- Preconception counseling, in classic (definite) antiphospholipid syndrome, 20
- Prednisone
 - for antiphospholipid antibody-related infertility, 29
 - for antiphospholipid syndrome during pregnancy, 20
 - in women with low levels of antibodies, 20
 - for prevention of pregnancy loss, in classic (definite) antiphospholipid syndrome, 20
- Preeclampsia
 - in antiphospholipid syndrome, 2
 - placental histopathology in, 11
- Pregnancy
 - adolescent
 - prevention of
 - contraception for, 114
 - long-term goals for, 114
 - parents' role in, 114
 - rate
 - trend in, 114
 - in U.S. *versus* other developed nations, 114
 - antiphospholipid syndrome management during, 20
 - antiretroviral therapy in, 154, 182
 - complications of
 - after myomectomy, 385
 - HIV infection and, 154
 - uterine leiomyomas and, 364, 385
 - degeneration of leiomyomas during, 364
 - ectopic, protection against, oral contraceptives and, 62

- in HIV-infected (AIDS) patients, 154
 - and AIDS-free survival, 154
 - and maternal-fetal conflicts, 300
 - maternal therapy for, 154, 182
 - and progression of disease, 154, 198
 - standards of care for, 210
 - studies of, advances in (future directions for), 154
 - and T-cell populations, 154
 - low-molecular-weight heparins in, 36
 - nausea and vomiting in. *See* Morning sickness
 - traditional Chinese medicine and, 801
 - unintended, rates of, 553
 - use of complementary and alternative medicine in, demographics of, 681
 - and warfarin therapy, 36
 - Pregnancy history, and risk of uterine rupture during trial of labor after previous cesarean, 604
 - Pregnancy loss
 - antiphospholipid antibody-related
 - clinically relevant antibodies in, 2
 - types of, 2
 - in antiphospholipid syndrome, 1, 11, 20
 - classification of, 2
 - embryonic
 - antiphospholipid antibody-associated, 2
 - definition of, 2
 - frequency of, 2
 - fetal, 2
 - antiphospholipid antibody-associated, 2
 - definition of, 2
 - frequency of, 2
 - in HIV-infected (AIDS) patients, 198
 - HIV infection and, 154
 - neonatal, 2
 - nomenclature of, 2
 - preembryonic
 - antiphospholipid antibody-associated, 2
 - definition of, 2
 - frequency of, 2
 - prevention of, in classic (definite) antiphospholipid syndrome, 20
 - recurrent
 - antiphospholipid antibody-associated, 2
 - prevalence of, 2
 - uterine leiomyomas and, 385
 - Pregnancy rate
 - after myomectomy, 385
 - HIV infection and, 154
 - Premarin, 864
 - Premature infant, kangaroo care for, 750
 - Premature rupture of membranes
 - and use of water in labor and birth, 733
 - uterine leiomyomas and, 364
 - Prematurity, in infants of HIV-infected mothers, 154, 182
 - antiretroviral therapy and, 243
 - Premenstrual syndrome, relief from
 - botanical medicine for, 853
 - depot medroxyprogesterone acetate and, 73
 - evening primrose for, 853
 - Prenatal care
 - historical perspective on, 671
 - Native Americans and, 661
 - Prenatal psychology, 750
 - Preterm delivery, in antiphospholipid syndrome, 2
 - Preterm labor, hypnotic relaxation for, 681
 - Progesterone, vaginal ring delivery system for, 106
 - Progestins. *See also* Estrogen/progestin combination
 - adverse effects and side effects of, 864
 - and growth of uterine leiomyomas, 372
 - in hormone replacement therapy, 464
 - implantable, mechanism of action of, 92
 - newer, in oral contraceptives, 62
 - noncontraceptive benefits of, 73
 - for postcoital contraception, 101
 - synthetic, vaginal ring delivery system for, 106
 - vaginal ring delivery system for, 106
 - Promensil, 853
 - Prostacyclin production, antiphospholipid antibodies
 - and, 11, 20
 - Prostaglandin E₂, for labor induction
 - after previous cesarean delivery, 588, 622
 - and risk of uterine rupture during trial of labor, 609
 - Prostate cancer, *BRC4* gene mutations and, 450
 - Protease inhibitors
 - adverse effects and side effects of, 243
 - mechanism of action of, 243
 - for pediatric AIDS, 243
 - use in pregnancy, preclinical and clinical data relevant to, 182
 - Protein C-protein S pathway, antiphospholipid antibodies
 - and, 11, 20
 - PTEN* gene, mutations, and hereditary breast cancer, 450
 - Pulmonary embolism, tamoxifen use and, 36
 - Puncture vine, 880
 - Pyridoxine, for morning sickness, 653
- Q
- Q fever, antiphospholipid antibodies in, 48
- Qi. *See* Chi (Qi)
- Quality of evidence, 588
 - Quinquefolius ginseng. *See* Ginseng, American
- R
- Radiation, and breast cancer risk, 478
 - Radiation therapy, for cervical cancer, 531
 - Radiation Therapy Oncology Group (RTOG), clinical trials of therapy for advanced cervical cancer, 531
 - Radiographic imaging
 - in cervical cancer, 485
 - in endometrial cancer, 485
 - in gestational trophoblastic disease, 485
 - in gynecologic oncology, 485
 - in ovarian cancer, 485
 - techniques for, 485
 - in tubal cancer, 485
 - in vaginal cancer, 485
 - in vulvar cancer, 485
 - RAD51L1* gene, 335
 - Raloxifene
 - for breast cancer prevention, 478
 - and thrombosis risk in antiphospholipid syndrome, 36
 - for uterine leiomyomas, 372
 - Raspberry leaf, 681
 - Rebirthing techniques, 750
 - Recombinant DNA technology, 425
 - Red degeneration, of uterine leiomyomas, 364
 - Reed's syndrome, 335
 - Reflexology

- in labor and delivery, 704
 - and neonatal healing, 750
 - Reflex testing, for human papillomavirus (HPV), 538
 - Regener-8, 893
 - Reiki, and neonatal healing, 750
 - Rejuvamax, 893
 - Relaxation, hypnotic
 - and labor induction, 681
 - for preterm labor, 681
 - Relaxation training, biofeedback and, 704
 - Remifemin, 853
 - Renewtrient, 893
 - Reproductive behavior, of HIV-infected women, 289
 - Reproductive decision-making, HIV infection and, 154
 - Reproductive dysfunction, uterine leiomyomas and, 364, 372, 385
 - Receptor. *See* Delavirdine
 - Reticulin staining, of uterine tumors, 350
 - Retinoids, in prevention of breast cancer, 478
 - Retrovir. *See* Zidovudine
 - Retroviral vector(s), for gene therapy, 425
 - Reverse transcriptase, 137
 - Reverse transcriptase inhibitors
 - non-nucleoside
 - adverse effects and side effects of, 243
 - mechanism of action of, 243
 - for pediatric AIDS, 243
 - use in pregnancy, preclinical and clinical data relevant to, 182
 - nucleoside
 - mechanism of action of, 243
 - mitochondrial toxicity of, 210, 243
 - for pediatric AIDS, 243
 - use in pregnancy, preclinical and clinical data relevant to, 182
 - Reviparin, for thrombosis in antiphospholipid syndrome, 36
 - RG13577*, therapeutic potential of, for uterine leiomyomas, 327
 - Rhabdomyolysis, uterine artery embolization for myomas and, 412
 - Rheumatoid arthritis, reduced risk of, oral contraceptives and, 62
 - Risk of Malignancy Index, 495
 - Ritonavir
 - for pediatric AIDS, 243
 - use in pregnancy, preclinical and clinical data relevant to, 182
 - Rokan, 814
 - RU486. *See* Mifepristone
- S
- Safrole, 853
 - SAME, Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 - Saquinavir, 243
 - use in pregnancy, preclinical and clinical data relevant to, 182
 - Sarcoma(s)
 - endometrial, poorly differentiated, 350
 - uterine
 - diagnosis of, 385
 - differential diagnosis of, 350
 - signs and symptoms of, 385
 - undifferentiated, 350
 - Saw palmetto
 - Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 - Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
 - Scintigraphy, in gynecologic oncology, 485
 - Screening tests
 - positive predictive value of, 522
 - sensitivity of, 522
 - specificity of, 522
 - Secretagogue HGH, 893
 - The Secret Life of the Unborn Child*, 750
 - Sedative-hypnotic, valerian as, 824
 - Sedative-hypnotics, kava kava as, 824
 - Semen, for artificial insemination, donor screening for HIV and, 276
 - Sentinel lymph nodes
 - detection of, in cervical cancer, 531
 - identification of, radiographic techniques for, 485
 - Sex hormone-binding globulin, 880
 - Sexual activity, and vertical transmission of HIV, 198
 - Sexual behavior, of HIV-infected women, 289
 - Sexually transmitted disease (STD)
 - in HIV-infected (AIDS) patients, 167, 226
 - incidence of, 289
 - risk factors for, 289
 - and risk of HIV transmission, 289
 - and HIV shedding, in female genital tract, 144, 226
 - interactions with HIV, 226, 289
 - and patient confidentiality, 300
 - treatment of, effect on HIV transmission, clinical trials of, 226
 - Sheppard-Towner Act (1921), 671
 - Shiatsu, 704
 - Siberian ginseng. *See* Ginseng
 - Simian immunodeficiency virus (SIV), 137, 144
 - SIV. *See* Simian immunodeficiency virus (SIV)
 - Skin
 - drug reactions affecting, in pediatric AIDS, 243
 - in pediatric AIDS, 243
 - Sleep, valerian and, 824
 - Smoking
 - and breast cancer risk, 478
 - and hemorrhagic stroke risk, 62
 - and ischemic stroke, 62
 - and myocardial infarction risk, 62
 - and thrombosis risk in antiphospholipid syndrome, 36
 - and uterine leiomyomas, 316
 - and vertical transmission of HIV, 198
 - Smooth muscle cell(s), of uterine leiomyomas
 - growth factors in, 327
 - as therapeutic target, 327, 372
 - Smooth muscle tumor(s)
 - in pediatric AIDS, 243
 - of uterine corpus. *See also specific tumor*
 - benign and malignant, differentiation of, 350
 - biologic behavior of, predictive factors for, 350
 - classification of, 350
 - clear cell, 350
 - clinical aspects of patient and, 350
 - coagulative tumor cell necrosis in, 350
 - cytologic atypia in, 350
 - differential diagnosis of, 350

- epithelioid, 350
- malignant, pathology of, 350
- mitotic activity in, 350
- myxoid, 350
- pathology of, 350
- plexiform, 350
- prognosis for, factors affecting, 350
- recurrence of, 350
- specific histologic subtypes of, 350
- of uncertain malignant potential, 350
- Somatopause, 893
- Sonohysterogram, of uterine leiomyomas, 385
- Sound therapy, in neonatal intensive care unit, 750
- Soybeans, isoflavones in, 836
- Soy protein, 836. *See also* Isoflavones; Phytoestrogens
 - adverse effects of, 836
 - and bone health, 836, 843
 - in breast cancer prevention, 836, 843
 - cardioprotective effects of, 843
 - and cognitive function, 843
 - effect on breast and endometrial cancer risk, 843
- Sperm, HIV in, 198
- Spermicide(s), contraceptive, for HIV-infected women, 226
- Spleen, in traditional Chinese medicine, 801
- Squamous intraepithelial lesions, in HIV-infected (AIDS) patients, 226
- St. John's wort
 - adverse effects and side effects of, 824
 - central nervous system effects of, 824
 - drug interactions with, 824
 - extracts, 824
 - safety of, 824
- Institute for Nutraceutical Advancement (INA) Methods Validation Program and, 789
- labeling of, 789
- potential detrimental effects of, 640, 789
- Standard precautions, for infection control, 276
- Stavudine
 - for pediatric AIDS, 243
 - in prevention of vertical transmission of HIV, 210
 - use in pregnancy, preclinical and clinical data relevant to, 182
- Sterile water blocks, for pain relief in labor, 704
- Sterilization, for HIV-infected (AIDS) patients, 289
- Stevens-Johnson syndrome, in pediatric AIDS patients, 243
- Stress physiology, 692
- Stroke
 - hemorrhagic, oral contraceptives and, 62
 - ischemic, oral contraceptives and, 62
 - risk
 - hormone replacement therapy and, 464
 - oral contraceptives and, 62
- Substance abuse
 - and sexual risk behavior in HIV-infected (AIDS) patients, 289
 - and vertical transmission of HIV, 198
- Superior vena caval thrombosis, in antiphospholipid syndrome, 36
- Surgery, traditional Chinese medicine and, 801
- Surveillance, for hereditary cancer, 450
- Sustiva. *See* Efavirenz
- Syphilis
 - antiphospholipid antibodies in, 48
 - in HIV-infected (AIDS) patients, 167
 - management of, 226
 - HIV seroprevalence among women with, 226
 - interactions with HIV, 226
- T
- Talc, perineal use of, and uterine leiomyomas, 316
- Tamoxifen
 - adverse effects and side effects of, 478
 - for breast cancer, 478
 - protective effect against breast cancer, 478
 - in *BRCA* gene mutation carriers, 450
 - and thrombosis risk in antiphospholipid syndrome, 36
 - for uterine leiomyomas, 372
- Tanakan, 814, 824
- 3TC. *See* Lamivudine
- Tebonin, 814, 824
- Testosterone
 - biochemistry of, 880
 - formulations of, 880
- ThinPrep cervical cancer screening, 538
- Thrombocytopenia
 - heparin-induced, 36
 - in pediatric AIDS, 243
- Thromboembolic disease
 - postpartum, 571
 - risk
 - hormone replacement therapy and, 464
 - raloxifene-related, 478
 - tamoxifen-related, 478
- Thrombolytic therapy, emergent, in antiphospholipid syndrome, 36
- Thromboprophylaxis
 - for antiphospholipid syndrome, 36
 - during pregnancy, 20
 - in classic (definite) antiphospholipid syndrome postpartum, 20
 - during pregnancy, 20
- Thrombosis
 - in antiphospholipid syndrome, 36
 - acute treatment of, 36
 - chronic treatment of, 36
 - platelet activation and, 11
 - in pregnancy, 2
 - recurrence rates for, 36
 - risk factors for, 36
 - placental, antiphospholipid antibody-associated, 11, 20
 - tamoxifen use and, 36
- Thromboxane production, antiphospholipid antibodies and, 11, 20
- Tibolone
 - androgenic effects of, 880
 - cardioprotective effects of, 880
 - clinical applications of, 880
 - for uterine leiomyomas, 372
- Tinzaparin, for thrombosis in antiphospholipid syndrome, 36
- Tobacco use. *See* Smoking
- Touch, therapeutic. *See also* Massage therapy; Reiki
 - in labor and delivery, 692, 704
 - and neonatal healing, 750

- Toxoplasmosis, in HIV-infected (AIDS) patients, management of, in pregnancy, 182
- TP53* gene, mutations, and hereditary breast cancer, 450
- Traditional Indian medicine, 661
- Transcutaneous electrical nerve stimulation (TENS)
advantages and disadvantages of, 704
for analgesia
after cesarean delivery, 704
efficacy of, 704
in labor and delivery, 704
mechanism of action of, 704
for incisional pain, 704
for labor analgesia, 704
in labor and delivery, 681
for lower back pain, 704
principles of, 681
- Transforming growth factor β , in fibrotic disease, 327
- Transfusion-related disorders, 571
- Tribulus terrestris*, 880
- Trichomoniasis
in HIV-infected (AIDS) patients, 167
interactions with HIV, 226
- Triest, 864
- Trinovic, 853
- Trissequens, 864
- Trisomy 12, and uterine leiomyomas, 335
- Tubal cancer
in *BRCA* gene mutation carriers, 450
metastases, 485
radiographic imaging in, 485
- Tuberculosis, in HIV-infected (AIDS) patients, management of, in pregnancy, 182
- U
- Ulcer(s)
chancroidal, interactions with HIV, 226
genital
herpes simplex virus, in HIV-infected (AIDS) patients, 167
management of, in pregnancy, 182
in HIV-infected (AIDS) patients, management of, 226
idiopathic, in HIV-infected (AIDS) patients, 167
interactions with HIV, 226
oral, herpes simplex virus, in HIV-infected (AIDS) patients, management of, in pregnancy, 182
- Ultrasound
of adnexal mass, 485, 495, 522
in diagnosis of ovarian pathology, 385
of hydatidiform mole, 485
in ovarian cancer screening, 522
pelvic, in gynecologic oncology, 485
transabdominal, in gynecologic oncology, 485
transvaginal
in gynecologic oncology, 485
of myomatous uterus, 385
in ovarian cancer surveillance, 450
of uterine leiomyomas, 385, 412
- Ulipant, 92
- Ureter(s)
compression of, by uterine leiomyomas, 364
obstruction, evaluation of, in gynecologic oncology, 485
- Urinary tract symptoms, estriol for, 864
- Urination, uterine leiomyomas and, 364, 385
- Urogenital atrophy, estriol for, 864
- USP. *See* US Pharmacopeia
- US Pharmacopeia
dietary supplement quality demonstration program, 789
Manufacturing Practices for Nutritional Supplements, 789
- Uterine artery embolization, for uterine leiomyomas, 412
advantages of, 412
adverse effects and side effects of, 412
anatomic considerations in, 412
complications of, 412
contraindications to, 412
fertility after, 412
historical perspective on, 412
mortality risk in, 412
patient selection for, 412
radiation dose to ovaries in, 412
results of, 412
success rates for, 412
technique for, 412
- Uterine bleeding
abnormal, with uterine leiomyomas, 364, 385
dysfunctional, in HIV-infected (AIDS) patients, 167
- Uterine rupture
after laparoscopy-assisted or laparoscopic myomectomy, 401
clinical signs of, 622
fetal monitor signs of, 622
high risk for, as contraindication to VBAC, 588
during trial of labor after previous cesarean, 561, 571, 604
breech presentation and, 588, 609
current pregnancy characteristics and, 609
dysfunctional labor and, 609
external cephalic version and, 588, 609
febrile morbidity after previous cesarean and, 609
gestation beyond EDD and, 609
interdelivery interval and, 609
labor induction or augmentation and, 609, 622
macrosomia and, 609
maternal age and, 609
multiple pregnancy and, 609
number of previous cesareans and, 609, 622
pregnancy history and, 609
previous vaginal deliveries and, 609
risk factors for, 609, 622
scar type and, 609, 622
thickness of lower uterine segment and, 609
uterine anomalies and, 609
- Uteroplacental insufficiency
in antiphospholipid syndrome, 2, 11, 20
complications of, prevention of, in classic (definite) antiphospholipid syndrome, 20
- Uterus
adenomatoid tumors of, 350
adenomyoma of, 350
anomalies of, and risk of uterine rupture during trial of labor, 609
atypical polypoid adenomyoma of, 350
compliance of, reduction of, by leiomyomas, 364
fibroids of. *See* Leiomyomata uteri
leiomyomas of. *See* Leiomyomata uteri

- lower segment of, thickness of, and risk of uterine rupture during trial of labor, 609
 - malignant mesenchymal neoplasms of, prevalence of, 350
 - mixed stromal/smooth muscle tumors of, 350
 - myomas of. *See* Leiomyomata uteri
 - rupture of. *See* Uterine rupture
 - sarcomas of. *See* Sarcoma(s)
 - smooth muscle tumors of. *See also specific tumor*
 - differential diagnosis of, 350
 - epithelioid, 350
 - myxoid, 350
 - pathology of, 350
 - specific histologic subtypes of, 350
 - of uncertain malignant potential, 350
 - traditional Chinese medicine and, 801
- V
- Vaccinia virus, as vector for gene therapy, 425
 - Vaginal birth, analgesia for, acupuncture in, 681
 - Vaginal birth after cesarean delivery, 553
 - ACOG position on, 561, 622
 - advances in (future directions for), 561
 - adverse outcomes for, 571
 - contraindications to, 588
 - controversy about, 561
 - cost analysis of, 571
 - cost-effectiveness analysis of, 571
 - eligibility for, 588
 - advances in (future directions for), 561
 - requirements for, 561
 - emergency response time and, 561, 622
 - European experience with, 594
 - fetal complications of, 571
 - high-risk case and, 594
 - historical perspective on, 561, 604
 - informed consent for, 622
 - intrapartum management of, 588, 622
 - legal risk with, reducing, 571, 622
 - management of, 594
 - maternal risks in, 571
 - medical risks with, reducing, 622
 - with previous single-layer closure, 622
 - rate of
 - in Europe, 604
 - trend in, 553
 - in United States, 604
 - safety of, 604. *See also* Uterine rupture
 - success of, after two or more previous cesarean deliveries, 561
 - in woman with multifetal pregnancy, 561
 - women's views on, 594
 - Vaginal bleeding, abnormal, with uterine leiomyomas, 364, 385
 - Vaginal cancer
 - radiographic imaging in, 485
 - staging of, 485
 - Vaginal intraepithelial neoplasia (VIN), in HIV-infected (AIDS) patients, 226
 - Vaginal ring hormone delivery system
 - benefits of, 106
 - clinical concerns with, 106
 - for contraception, agents for, 106
 - discoloration with, 106
 - for menopausal symptoms, 106
 - odor with, 106
 - removal of, for intercourse, 106
 - ring design, 106
 - size of, 106
 - vaginal discharge with, 106
 - Vaginitis, in HIV-infected (AIDS) patients
 - incidence of, 226
 - microbiology of, 226
 - prevalence of, 226
 - treatment of, 226
 - Valerian
 - Association of Official Agricultural Chemists' task force on dietary supplements and, 789
 - extracts
 - adverse effects and side effects of, 824
 - pharmacologic properties of, 824
 - Vasomotor symptoms, menopausal
 - botanical medicine for, 836, 853
 - estriol for, 864
 - hormone replacement therapy and, 464
 - phytoestrogens and, 836
 - Vasopressin
 - and blood loss during myomectomy, 385
 - in laparoscopic myomectomy, 401
 - Venous insufficiency, chronic, horse chestnut for, 814
 - Venous pathology, horse chestnut for, 814
 - Venous thrombosis/thromboembolism
 - in antiphospholipid syndrome, 36
 - acute treatment of, 36
 - risk factors for, 36
 - oral contraceptives and, 62
 - Videx. *See* Didanosine
 - Viracept. *See* Nelfinavir
 - Viral infection(s), in pediatric AIDS, 243
 - Viramune. *See* Nevirapine
 - Vital substances, in traditional Chinese medicine, 801
 - Vitamin B₆. *See* Pyridoxine
 - Vitex
 - drug interactions with, 853
 - indications for, in reproductive medicine, 853
 - for menopausal symptoms, 853
 - Vomiting, pregnancy-associated. *See* Morning sickness
 - Vulvar cancer
 - groin node metastases of, 485
 - radiographic imaging in, 485
 - staging of, 485
 - Vulvar intraepithelial neoplasia (VIN), in HIV-infected (AIDS) patients, 226
- W
- Warfarin
 - in antiphospholipid syndrome
 - chronic therapy with, 36
 - complications of, 36
 - postpartum therapy with, in classic (definite) antiphospholipid syndrome, 20
 - pregnancy and, 36
 - Water, use of, in labor and birth, 733. *See also* Hydrotherapy; Sterile water blocks
 - benefits of, 733
 - maternal, 733
 - neonatal, 733

- cleaning of tub used in, 733
- contraindications to, 733
- eligibility for, 733
- equipment for, 733
- historical perspective on, 733
- and maternal or neonatal infection, 733
- maternal outcomes with, 733
- maternal satisfaction with, 733
- neonatal outcomes with, 733
- rationale for, 733
- recommendations for, 733
- safety of, 733
- trends in, 733
- Weight changes
 - with implantable contraceptives, 92
 - with injectable long-acting contraceptives, 73
- Weight loss
 - in HIV-infected (AIDS) patients, management of, in women, 167
 - as presenting HIV-related condition, 167
- Well-being, improvements in
 - dehydroepiandrosterone and, 880
 - growth hormone and, 893
- Western blot, for HIV detection, 167
- Wild yam creams, 853
- Women's health status, survey of, in United States, 553
- X
- X chromosome, abnormalities, and uterine leiomyomas, 335
- Y
- Yam extracts. *See* Wild yam creams
- Yin/yang principle, 704, 801
- Yohimbine, Association of Official Agricultural Chemists' task force on dietary supplements and, 789
- Z
- Zalcitabine, use in pregnancy, preclinical and clinical data relevant to, 182
- ZDV. *See* Zidovudine
- Zerit. *See* Stavudine
- Ziagen. *See* Abacavir
- Zidovudine
 - adverse effects and side effects of, 210
 - effect on vertical transmission of HIV, 154, 210, 243
 - mutagenicity of, 210, 243
 - neonatal therapy with, 210, 243
 - for pediatric AIDS, 243
 - pharmacokinetics of, in pregnancy, 182, 210
 - postexposure prophylaxis
 - for neonate, 243
 - with occupational HIV exposure, 276
 - regimens for, 276
 - resistance to, 210
 - teratogenicity of, 182, 210
 - toxicity of, 182
 - use in pregnancy, 243
 - long-term effects of, 182, 210, 243
 - preclinical and clinical data relevant to, 182, 210
 - and prevention of vertical transmission of HIV, 210, 243
 - safety of, 210
- Zoladex, preoperative use of, with myomectomy, 385

Author Index

- Ahdieh, Linda, 154
Albers, Leah L., 692
Al-Harthi, Lena, 144
Allaire, Alexander D., 681
Anthony, Mary S., 843
Archer, David F., 60, 122
Assemi, Mitra, 824
Atkins, Meredith, 604
Baker, Vicki V., 522
Ballagh, Susan A., 106
Barnhart, Kurt, 92
Basil, Jack B., 464
Beckett, Virginia A., 594
Benda, Jo Ann, 350
Bloss, Jeffrey D., 478
Branch, D. Ware, 1, 2
Burger, Harold, 137
Burgess, Traci, 198
Burkman, Ronald T., 62
Chambliss, Linda R., 639, 640
Chandramouli, Nitin B., 36
Chavez, Norma F., 372
Christman, Gregory M., 425
Clark, Rebecca A., 167
Cline, J. Mark, 843
Cohen, Bruce, 604
Cohn, David E., 538
Davis, Ann J., 114
Dennehy, Cathi, 814
Dovey, Michael, 801
Esplin, M. Sean, 20
Ferreiro, Roxana B., 276
Flamm, Bruce L., 622
Fowler, Jeffrey M., 495
Geis, William, 2
Gentz, Brenda A., 704
Gharavi, Azzudin E., 11, 48
Goldman, Erik L., 789
Goodwin, Scott C., 412
Greulich, Mary Beth, 692
Grigsby, Perry W., 531
Gross, Karen L., 335
Guarnaccia, Michael M., 385
Harris, E. Nigel, 11, 48
Herzog, Thomas J., 531, 538
Hoffman, Freddie Ann, 780
Hosmer, Lucy, 671
Hughes, Ellen F., 774, 902
Jones, Jamieson E., 750
Kassity, Nadine, 750
Kaunitz, Andrew M., 73
Kayne, Martha A., 692
Khorram, Omid, 880, 893
Khoury, Margaret, 243
Kobelin, Cindy Gail, 588
Korn, Abner P., 226
Kovacs, Andrea, 243
Kovalevsky, George, 92
Landay, Alan, 144
Levy, Roger A., 11
Lieberman, Ellice, 609
Mackey, Miranda M., 733
Manolitsas, Tom P., 495
McCarthy, Jenifer D., 425
Milad, Magdy P., 401
Minkoff, Howard, 135, 210
Molina, John W., 661
Morton, Cynthia C., 335
Mutch, David G., 449, 464
Nestler, Gary, 801
November, Martin T., 571
Nowak, Romana A., 327
Pierangeli, Silvia S., 11, 48
Porter, T. Flint, 29
Powderly, Kathleen, 300
Regan, Lesley, 594
Reim, Mitchell S., 385
Rodabaugh, Kerry J., 478
Rodgers, George M., 36
Sachs, Benjamin P., 552, 553
Sankpal, Rajendra S., 401
Schwartz, Stephen M., 316
Sepkowitz, Kent A., 276
Soper, John T., 485
Stewart, Elizabeth A., 372
Stovall, Dale W., 364
Strong, Thomas H., Jr., 653
Swisher, Elizabeth, 450
Taylor, Maida, 771, 853, 864
Thomas, Michael A., 101
Tsourounis, Candy, 836
Van Voorhis, Bradley, 314
Wagner, Janice D., 843
Watts, D. Heather, 182
Weiser, Barbara, 137
Wilson, Tracey E., 289
Wong, Gordon C. H., 412
Young, Mary A., 167
Zinberg, Stanley, 561

